US20080103181A9 - Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases - Google Patents
Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases Download PDFInfo
- Publication number
- US20080103181A9 US20080103181A9 US10/561,153 US56115304A US2008103181A9 US 20080103181 A9 US20080103181 A9 US 20080103181A9 US 56115304 A US56115304 A US 56115304A US 2008103181 A9 US2008103181 A9 US 2008103181A9
- Authority
- US
- United States
- Prior art keywords
- isoindol
- dioxo
- octahydro
- benzamide
- ethenocycloprop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 [1*]C([3*])C1C(=O)N(N([5*])C([6*])=O)C(=O)C1C([2*])[4*] Chemical compound [1*]C([3*])C1C(=O)N(N([5*])C([6*])=O)C(=O)C1C([2*])[4*] 0.000 description 17
- CSKDFZIMJXRJGH-UHFFFAOYSA-N [H]C12CC1([H])C1C=CC2C2([H])C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)C12[H] Chemical compound [H]C12CC1([H])C1C=CC2C2([H])C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)C12[H] CSKDFZIMJXRJGH-UHFFFAOYSA-N 0.000 description 2
- IVYPVGFVVJXQCM-ADPPZMDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC(F)=CC=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC(F)=CC=C3)C(=O)[C@]12[H] IVYPVGFVVJXQCM-ADPPZMDZSA-N 0.000 description 2
- GQGOBOCEBRFFFK-AALLWRQTSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CSC=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CSC=C3)C(=O)[C@]12[H] GQGOBOCEBRFFFK-AALLWRQTSA-N 0.000 description 2
- HSZNSVLYPJLCRF-GHXBURCUSA-N [H][C@@]12C(=O)N(NC(=O)C3=C(Cl)C=C(Cl)C=C3)C(=O)[C@]1([H])C1C=CC2C1 Chemical compound [H][C@@]12C(=O)N(NC(=O)C3=C(Cl)C=C(Cl)C=C3)C(=O)[C@]1([H])C1C=CC2C1 HSZNSVLYPJLCRF-GHXBURCUSA-N 0.000 description 2
- KNUOUEDISNFRIY-JSHBZLHNSA-N [H][C@@]12C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]1([H])C1C=CC2CCC1 Chemical compound [H][C@@]12C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]1([H])C1C=CC2CCC1 KNUOUEDISNFRIY-JSHBZLHNSA-N 0.000 description 2
- QNBIPDPKATXWOJ-SUBVLCJKSA-N [H][C@@]12C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]1([H])C1CCC2CC1 Chemical compound [H][C@@]12C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]1([H])C1CCC2CC1 QNBIPDPKATXWOJ-SUBVLCJKSA-N 0.000 description 2
- RWGFKTVRMDUZSP-UHFFFAOYSA-N CC(C)C1=CC=CC=C1 Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 1
- GNZBERNORFJFJT-CNHKKPJLSA-N [H]C12CC1([H])C1C(C)=C(C)C2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C(C)=C(C)C2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] GNZBERNORFJFJT-CNHKKPJLSA-N 0.000 description 1
- AZNCJZUWAHJCLB-YOHVKPHQSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(N(C)C(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(N(C)C(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] AZNCJZUWAHJCLB-YOHVKPHQSA-N 0.000 description 1
- PDTWJALCALXIIH-CNHKKPJLSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(N(CC)C(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(N(CC)C(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] PDTWJALCALXIIH-CNHKKPJLSA-N 0.000 description 1
- LHPDNQMEZBYLEE-UEZNURIYSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C34CC5CC(CC(C5)C3)C4)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C34CC5CC(CC(C5)C3)C4)C(=O)[C@]12[H] LHPDNQMEZBYLEE-UEZNURIYSA-N 0.000 description 1
- OLFJAAPWKAVFKS-GBMNLJDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=C(Br)C=CC=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=C(Br)C=CC=C3)C(=O)[C@]12[H] OLFJAAPWKAVFKS-GBMNLJDZSA-N 0.000 description 1
- CPRMSEKYJFJGII-AALLWRQTSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=C(C)N=C(C)S3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=C(C)N=C(C)S3)C(=O)[C@]12[H] CPRMSEKYJFJGII-AALLWRQTSA-N 0.000 description 1
- ATWGPAAGZWQRJW-GBMNLJDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=C(Cl)C=CC=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=C(Cl)C=CC=C3)C(=O)[C@]12[H] ATWGPAAGZWQRJW-GBMNLJDZSA-N 0.000 description 1
- QRWZSMGXNJSJBA-ADPPZMDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]12[H] QRWZSMGXNJSJBA-ADPPZMDZSA-N 0.000 description 1
- XIDCFAYBJPWRRW-YOHVKPHQSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(C#N)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(C#N)C=C3)C(=O)[C@]12[H] XIDCFAYBJPWRRW-YOHVKPHQSA-N 0.000 description 1
- CSKDFZIMJXRJGH-ADPPZMDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] CSKDFZIMJXRJGH-ADPPZMDZSA-N 0.000 description 1
- WRNZHKUBWSDTRF-YOHVKPHQSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(C)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(C)C=C3)C(=O)[C@]12[H] WRNZHKUBWSDTRF-YOHVKPHQSA-N 0.000 description 1
- USPKYYZDABFFSZ-ADPPZMDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(Cl)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(Cl)C=C3)C(=O)[C@]12[H] USPKYYZDABFFSZ-ADPPZMDZSA-N 0.000 description 1
- YIRDWOBUQUNSNY-ADPPZMDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(F)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(F)C=C3)C(=O)[C@]12[H] YIRDWOBUQUNSNY-ADPPZMDZSA-N 0.000 description 1
- ZPZCRHNAIUYXKE-YOHVKPHQSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(OC)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(OC)C=C3)C(=O)[C@]12[H] ZPZCRHNAIUYXKE-YOHVKPHQSA-N 0.000 description 1
- AGTXHHZRNMTLHL-ADPPZMDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C([N+](=O)[O-])C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C([N+](=O)[O-])C=C3)C(=O)[C@]12[H] AGTXHHZRNMTLHL-ADPPZMDZSA-N 0.000 description 1
- IYWDNVOMIGEONH-ADPPZMDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=CC(Br)=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=CC(Br)=C3)C(=O)[C@]12[H] IYWDNVOMIGEONH-ADPPZMDZSA-N 0.000 description 1
- KVTCHDSYFPESLK-ADPPZMDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=CC(Cl)=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=CC(Cl)=C3)C(=O)[C@]12[H] KVTCHDSYFPESLK-ADPPZMDZSA-N 0.000 description 1
- PGAGSPWHPNHQCY-RLOIFVPSSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=CN=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=CN=C3)C(=O)[C@]12[H] PGAGSPWHPNHQCY-RLOIFVPSSA-N 0.000 description 1
- RGTBYNJLXMRUQN-RLOIFVPSSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=NC=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=CC=NC=C3)C(=O)[C@]12[H] RGTBYNJLXMRUQN-RLOIFVPSSA-N 0.000 description 1
- UOHVZYYJHRCWBD-UHPCZEEKSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=NC=CC=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3=NC=CC=C3)C(=O)[C@]12[H] UOHVZYYJHRCWBD-UHPCZEEKSA-N 0.000 description 1
- DMQIKGOJSPZYLP-ADPPZMDZSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3CCCCC3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)C3CCCCC3)C(=O)[C@]12[H] DMQIKGOJSPZYLP-ADPPZMDZSA-N 0.000 description 1
- CVVKETMOOFDHOM-UMXUKVQPSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)CC3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)CC3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] CVVKETMOOFDHOM-UMXUKVQPSA-N 0.000 description 1
- MSJDEALLCYFPIJ-UMXUKVQPSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)CC3=CC=CC=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)CC3=CC=CC=C3)C(=O)[C@]12[H] MSJDEALLCYFPIJ-UMXUKVQPSA-N 0.000 description 1
- HGOZFVZTVSHXND-MGXKEQJRSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)CC3=CC=NC=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)CC3=CC=NC=C3)C(=O)[C@]12[H] HGOZFVZTVSHXND-MGXKEQJRSA-N 0.000 description 1
- OQPSLLKXDOIOQW-QRFKRNBUSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)CC=C)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(=O)CC=C)C(=O)[C@]12[H] OQPSLLKXDOIOQW-QRFKRNBUSA-N 0.000 description 1
- PVURAYFJHUXZCT-YZGMSDOFSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(C)=O)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)N(NC(C)=O)C(=O)[C@]12[H] PVURAYFJHUXZCT-YZGMSDOFSA-N 0.000 description 1
- QMLYJZNAGFCCGP-XIDJMXOJSA-N [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)OC(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1C=CC2[C@]2([H])C(=O)OC(=O)[C@]12[H] QMLYJZNAGFCCGP-XIDJMXOJSA-N 0.000 description 1
- NHMSINHXUXEFJT-ADPPZMDZSA-N [H]C12CC1([H])C1CCC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1CCC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]12[H] NHMSINHXUXEFJT-ADPPZMDZSA-N 0.000 description 1
- XOHZZDFJOIMTMY-ADPPZMDZSA-N [H]C12CC1([H])C1CCC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1CCC2[C@]2([H])C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]12[H] XOHZZDFJOIMTMY-ADPPZMDZSA-N 0.000 description 1
- NWWNOEMICJNZCT-XIDJMXOJSA-N [H]C12CC1([H])C1CCC2[C@]2([H])C(=O)OC(=O)[C@]12[H] Chemical compound [H]C12CC1([H])C1CCC2[C@]2([H])C(=O)OC(=O)[C@]12[H] NWWNOEMICJNZCT-XIDJMXOJSA-N 0.000 description 1
- KJDNIXCMYMBSNO-UHFFFAOYSA-N [H]N(C(=O)C1=CC=C(Br)C=C1)N1C(=O)C2CCCCC2C1=O Chemical compound [H]N(C(=O)C1=CC=C(Br)C=C1)N1C(=O)C2CCCCC2C1=O KJDNIXCMYMBSNO-UHFFFAOYSA-N 0.000 description 1
- RIMPTBZGDBXUFE-UZIHZSBWSA-N [H][C@@]12C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]1([H])C1C=CC2C1 Chemical compound [H][C@@]12C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]1([H])C1C=CC2C1 RIMPTBZGDBXUFE-UZIHZSBWSA-N 0.000 description 1
- CJAXQEDNHWIMQB-SUBVLCJKSA-N [H][C@@]12C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]1([H])C1C=CC2CC1 Chemical compound [H][C@@]12C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]1([H])C1C=CC2CC1 CJAXQEDNHWIMQB-SUBVLCJKSA-N 0.000 description 1
- LXMVJTNCOZWYQZ-SUBVLCJKSA-N [H][C@@]12C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]1([H])C1CCC2CC1 Chemical compound [H][C@@]12C(=O)N(NC(=O)C3=CC=C(Br)C=C3)C(=O)[C@]1([H])C1CCC2CC1 LXMVJTNCOZWYQZ-SUBVLCJKSA-N 0.000 description 1
- RKZGYYBYKYLFHY-SUBVLCJKSA-N [H][C@@]12C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]1([H])C1C=CC2C=C1 Chemical compound [H][C@@]12C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]1([H])C1C=CC2C=C1 RKZGYYBYKYLFHY-SUBVLCJKSA-N 0.000 description 1
- BVOSYXIKTYKMPL-SUBVLCJKSA-N [H][C@@]12C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]1([H])C1C=CC2CC1 Chemical compound [H][C@@]12C(=O)N(NC(=O)C3=CC=C(C(F)(F)F)C=C3)C(=O)[C@]1([H])C1C=CC2CC1 BVOSYXIKTYKMPL-SUBVLCJKSA-N 0.000 description 1
- XOVTYEHPLKSKDZ-LLZFXZEUSA-N [H][C@@]12C(=O)N(NC(=O)C3=CC=CC(Br)=C3)C(=O)[C@]1([H])C1C=CC2C12CC2 Chemical compound [H][C@@]12C(=O)N(NC(=O)C3=CC=CC(Br)=C3)C(=O)[C@]1([H])C1C=CC2C12CC2 XOVTYEHPLKSKDZ-LLZFXZEUSA-N 0.000 description 1
- YIHKILSPWGDWPR-HYNHDVCUSA-N [H][C@@]12C(=O)OC(=O)[C@]1([H])C1C=CC2CC1 Chemical compound [H][C@@]12C(=O)OC(=O)[C@]1([H])C1C=CC2CC1 YIHKILSPWGDWPR-HYNHDVCUSA-N 0.000 description 1
- FGVZZSVCYPXXAC-WZENYGAOSA-N [H][C@@]12C(=O)OC(=O)[C@]1([H])C1C=CC2CCC1 Chemical compound [H][C@@]12C(=O)OC(=O)[C@]1([H])C1C=CC2CCC1 FGVZZSVCYPXXAC-WZENYGAOSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Definitions
- the present invention relates to the use of di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
- the Orthopox genus (Orthopoxviridae) is a member of the Poxviridae family and the Choropoxivirinae subfamily.
- the genus consists of numerous viruses that cause significant disease in human and animal populations. Viruses in the orthopox genus include cowpox, monkeypox, vaccina, and variola (smallpox), all of which can infect humans.
- the smallpox (variola) virus is of particular importance. Recent concerns over the use of smallpox virus as a biological weapon has underscored the necessity of developing small molecule therapeutics that target orthopoxviruses. Variola virus is highly transmissible and causes severe disease in humans resulting in high mortality rates (Henderson et al. (1999) JAMA. 281:2127-2137). Moreover, there is precedent for use of variola virus as a biological weapon. During the French and Indian wars (1754-1765), British soldiers distributed blankets used by smallpox patients to American Indians in order to establish epidemics (Stern, E. W. and Stern A. E. 1945. The effect of smallpox on the destiny of the Amerindian. Boston).
- Variola virus is naturally transmitted via aerosolized droplets to the respiratory mucosa where replication in lymph tissue produces asymptomatic infection that lasts 1-3 days. Virus is disseminated through the lymph to the skin where replication in the small dermal blood vessels and subsequent infection and lysis of adjacent epidermal cells produces skin lesions (Moss, B. (1990) Poxyiridae and Their Replication, 2079-2111. In B. N. Fields and D. M. Knipe (eds.), Fields Virology. Raven Press, Ltd., New York). Two forms of disease are associated with variola virus infection; variola major , the most common form of disease, which produces a 30% mortality rate and variola minor , which is less prevalent and rarely leads to death ( ⁇ 1%). Mortality is the result of disseminated intravascular coagulation, hypotension, and cardiovascular collapse, that can be exacerbated by clotting defects in the rare hemorrhagic type of smallpox (Moss, supra).
- monkeypox virus A recent outbreak of monkeypox virus underscores the need for developing small molecule therapeutics that target viruses in the orthpox genus. Appearance of monkeypox in the US represents an emerging infection. Monkeypox and smallpox cause similar diseases in humans, however mortality for monkeypox is lower (1%).
- Vaccination is the current means for preventing orthopox virus disease, particularly smallpox disease.
- the smallpox vaccine was developed using attenuated strains of vaccinia virus that replicate locally and provide protective immunity against variola virus in greater than 95% of vaccinated individuals (Modlin (2001) MMWR (Morb Mort Wkly Rep) 50:1-25).
- Adverse advents associated with vaccination occur frequently (1:5000) and include generalized vaccinia and inadvertent transfer of vaccinia from the vaccination site. More serious complications such as encephalitis occur at a rate of 1:300,000, which is often fatal (Modlin, supra). The risk of adverse events is even more pronounced in immunocompromised individuals (Engler et al.
- VIG Vaccinia virus immunoglobulin
- VIG is an isotonic sterile solution of immunoglobulin fraction of plasma derived from individuals who received the vaccinia virus vaccine. It is used to treat eczema vaccinatum and some forms of progressive vaccinia. Since this product is available in limited quantities and difficult to obtain, it has not been indicated for use in the event of a generalized smallpox outbreak (Modlin, supra).
- Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] [HPMPC] is a nucleoside analog approved for treatment of CMV retinitis in AIDS patients. Cidofovir has been shown to have activity in vitro against a number of DNA containing viruses including adenovirus, herpesviruses, hepadnaviruses, polyomaviruses, papillomaviruses, and ortho poxviruses (Bronson et al. (1990) Adv. Exp. Med. Biol. 278:277-83; De Clercq et al. (1987) Antiviral Res.
- viruses including adenovirus, herpesviruses, hepadnaviruses, polyomaviruses, papillomaviruses, and ortho poxviruses
- Cidofovir has also been found to inhibit authentic variola virus replication (Smee et al. (2002) Antimicrob. Agents Chemother. 46:1329-1335).
- Cidofovir is poorly bioavailable and must be administered intravenously (Lalezari et al. (1997) Ann. Intern. Med. 126:257-263). Moreover, cidofovir produces dose-limiting nephrotoxicity upon intravenous administration (Lalezari et al.). In addition, cidofovir-resistance has been noted for multiple viruses. Cidofovir-resistant cowpox, monkeypox, vaccinia, and camelpox virus variants have been isolated in the laboratory by repeated passage in the presence of drug (Smee, supra).
- Cidofovir-resistance represents a significant limitation for use of this compound to treat orthopoxvirus replication.
- the poor bioavailability, need for intravenous administration, and prevalence of resistant virus underscores the need for development of additional and alternative therapies to treat orthopoxvirus infection.
- methisazone the prototypical thiosemicarbazone
- methisazone has been used in the prophylactic treatment of smallpox infections (Bauer et al. (1969) Am. J Epidemiol. 90:130-145).
- this compound class has not garnered much attention since the eradication of smallpox due to generally unacceptable side effects such as severe nausea and vomiting.
- Mechanism of action studies suggest that methisazone interferes with translation of L genes (De Clercq (2001), supra).
- methisazone is a relatively non-specific antiviral compound and can inhibit a number of other viruses including adenoviruses, picornaviruses, reoviruses, arboviruses, and myxoviruses (Id.).
- SAH S-adenosylhomocysteine hydrolase
- orthopoxviruses including cowpox, monkeypox, camelpox, variola, and probably most other mammalian orthopoxviruses, can be grown readily in cell culture and produce robust cytopathic effect (CPE) in 3 to 5 days. Since this CPE is directly related to viral replication, compounds that inhibit virus replication in cell culture can be identified readily as conferring protection from virus-induced CPE (although it is theoretically possible to inhibit CPE without inhibiting virus replication). Moreover, compounds having identified activity against cowpox virus will also likely be active against human variola virus given the high degree of homology (>95%) between these two viruseshe replication proteins of orthopoxviruses are highly homologous.
- viruses diverge in regions of their genomes that encode immuno-modulatory functions (host-specific). Additionally, many compounds have been identified in the literature that inhibit orthopoxvirus replication in cell culture and there are few, if any, examples were a compound is dramatically more potent against a one species of orthopoxvirus and not the others
- the present invention provides compounds and compositions and/or methods for the treatment and prophylaxis of viral infections, as well as diseases associated with viral infections in living hosts.
- the compounds of the invention are of the following general formula:
- R 1 and R 2 represent radicals independently selected from the group consisting of hydrogen and alkyl
- R 3 and R 4 represent radicals independently selected from the group consisting of hydrogen and alky
- R 3 and R 4 taken together with the carbons to which they are attached form a cyclic structure selected from the group consisting of wherein R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 represent radicals that are independently selected from the group consisting of hydrogen and alkyl;
- R 5 represents a radical selected from the group consisting of hydrogen and alkyl
- R 6 represents a radical selected from the group consisting of straight- or branched chain alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, cycloalkenyl, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group selected from the group consisting of furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, and tetrazolyl; a substituted or unsubstituted arylalkyl group, and a substituted or unsubstituted heteroarylalkyl group, wherein the heteroaryl is selected from the group consisting pyridine and thiophene;
- M is selected from the group consisting of wherein R 13 , R 14 , R 15 , and R 16 are independently selected from the group consisting of hydrogen and alkyl;
- said aryl group substituents and said arylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- heteroaryl group substituents and said heteroarylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, amino, monoalkylamino, dialkylamino, aminoalkyl, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- the invention also relates to pharmaceutical compositions containing the antiviral compounds of Formula I and the corresponding methods of use for treating and preventing infections caused by orthopox viruses.
- the instant invention provides compounds of Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and M are as defined above, with the proviso that said formula does include the compounds selected from the group consisting of N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-4-pyridinecarboxamide; 4-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 3-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-etheno
- Preferred compounds of Formula I include the compounds of Formula Ia: wherein:
- R 6 represents a radical selected from the group consisting of straight- or branched chain allyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, cycloalkenyl, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group selected from the group consisting of furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, and tetrazolyl; a substituted or unsubstituted arylalkyl group, and a substituted or unsubstituted heteroarylalkyl group, wherein the heteroaryl is selected from the group consisting pyridine and thiophene;
- said aryl group substituents and said arylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- heteroaryl group substituents and said heteroarylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, amino, monoalkylamino, dialkylamino, aminoalkyl, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- Another preferred aspect of the invention includes the compounds of Formula Ib: wherein:
- R 6 represents a radical selected from the group consisting of straight- or branched chain alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, cycloalkenyl, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group selected from the group consisting of furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, and tetrazolyl; a substituted or unsubstituted arylalkyl group, and a substituted or unsubstituted heteroarylalkyl group, wherein the heteroaryl is selected from the group consisting pyridine and thiophene;
- said aryl group substituents and said arylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- heteroaryl group substituents and said heteroarylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, amino, monoalkylamino, dialkylamino, aminoalkyl, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- Preferred compounds of the invention include 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethanocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-bromo-N-(octahydro-1,3-dioxo-2H-isoindol-2-yl)-benzamide; 4-fluoro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(
- Another aspect of the invention includes the compounds selected from the group consisting of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 2-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-3-pyridinecarboxamide; N-(3,3a,4,4a,5,5a,6,6a-oct
- the compound may be selected from any of the compounds described, supra.
- the present invention provides a method for preventing and treating orthopoxvirus infections and for preventing and treating diseases associated with such infections in a living host (for example, a mammal including a human) having or susceptible to an orthopoxvirus infection, comprising the step of administering to the living host a therapeutically effective amount of a compound of the formula:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and M are as defined for compounds of Formula I above, or a pharmaceutically acceptable salt to a host susceptible to, or suffering from such infection.
- a preferred method includes the prevention and treatment of orthopoxvirus infections and diseases associated with such infections in a living host having or susceptible to an orthopoxvirus infection, comprising the step of administering a therapeutically effective amount of the compounds of the Formula Ia, above, or a pharmaceutically acceptable salt thereof.
- Another preferred method includes the prophylaxis or treatment of orthopoxvirus infections and diseases associated with such infections in a living host having or susceptible to an orthopoxvirus infection, comprising the step of administering a therapeutically effective amount of the compounds of the Formula Ib, above or a pharmaceutically acceptable salt, thereof.
- the present invention additionally provides methods for the treatment or prevention of infections caused by an orthopox virus wherein the orthopox virus is selected from the group consisting of vaccinia virus, cowpox virus, smallpox (variola) virus, monkeypox virus and camelpox virus; in a living host (for example, a mammal including a human) comprising the step of administering a therapeutically effective amount of the compounds of the invention to a host susceptible to, or suffering from such infection.
- vaccinia virus cowpox virus, smallpox (variola) virus, monkeypox virus and camelpox virus
- a living host for example, a mammal including a human
- the present invention provides a pharmaceutical composition for the treatment or prevention of orthopoxvirus infections and diseases associated with such infections in a living host, that comprises a therapeutically effective amount of one or more of the compounds of the formula:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and M are as defined for compounds of Formula I above, and a pharmaceutically acceptable carrier medium.
- the compounds of the invention described herein, their isomers and pharmaceutically acceptable salts exhibit antiviral activity.
- the compounds of the invention are particularly effective against orthopoxviruses, and are useful in the prophylaxis and/or treatment of infections and diseases associated with this virus in living hosts.
- orthopoxviruses examples include, but are not limited to, aractuba virus, BeAn 58058 virus, buffalopox virus, camelpox virus (such as Camelpox virus 903, Camelpox virus CMG, Camelpox virus CMS, Camelpox virus CP1, Camelpox virus CP5, and Camelpox virus M-96), cantagalo orthopoxvirus, cowpox virus (such as Cowpox virus strain Hamburg-1985 and Cowpox virus strain Turkmenia-1974), Ectromelia virus (such as Belo Horizonte virus), elephantpox virus, monkeypox virus (such as Monkeypox virus strain Sierra Leone 70-0266 and Monkeypox virus strain Zaire 77-0666), rabbitpox virus (such as Rabbitpox strain Utrecht), raccoonpox virus, skunkpox virus, taterapox virus, vaccinia
- antiviral activity of representative compounds was evaluated in assays that measure the ability of compounds to protect cells from virus-induced CPE.
- Cells that will support growth of the particular orthopox virus strain are seeded into 96-well tissue culture treated plates and then infected with an amount of the appropriate orthopox virus strain that results in complete CPE in ⁇ 3 days.
- Various dilutions of inhibitory compound(s) are added and the plates are incubated at the appropriate temperature for optimal virus growth. At the end of the incubation period, cells are fixed with glutaraldehyde and stained with crystal violet.
- Cell protection is measured spectrophotometrically at OD 570 nm.
- the interpolated compound dilution that results in 50% protection of the cell monolayer from virus-induced CPE is calculated and reported as the 50% effective concentration or EC 50 .
- Antiviral activity of representative compounds described herein occurred at drug concentrations that had no demonstrable effect on cell growth, indicating that the compounds were working specifically by an antiviral mechanism.
- the term “compounds of the invention” means, collectively, the compounds of Formula I, pharmaceutically acceptable salts thereof, their isomers, and mixtures thereof.
- the compounds of the invention are identified herein by their chemical structure and/or chemical name. Where a compound is referred to by both a chemical structure and a chemical name, and that chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.
- living host refers to an organism that is living and capable of being infected with a virus, such as an orthopoxvirus; for example, a mammal, which includes a human.
- a virus such as an orthopoxvirus
- alkyl refers to straight or branched chain aliphatic hydrocarbon radicals of up to 10 carbon atoms, preferably up to 6 carbon atoms and more preferably 1 to 4 carbon atoms.
- substituents such as alkoxy (—O-alkyl), allylthio (—S-alkyl), monoalkylamino (—NH-alkyl), dialkylamino, (—N-(alkyl)alkyl), alkylsulfonyl (—S(O) 2 -alkyl), carboxyalkyl (-alkyl-COOH), or the like, also refers to aliphatic hydrocarbon radicals of one to six carbon atoms, and preferably of one to four carbon atoms.
- alk in structural formula denotes an alkyl group, unless divalency is indicated in which case the “alk” denotes the corresponding alkylene group(s). Additionally, the term “lower alkyl” denotes an alkyl group having one to four carbon atoms.
- alkenyl refers to straight or branched chain aliphatic hydrocarbon radicals of 2 to 7 carbon atoms containing one double bond. Such alkenyl moieties may exist in the E or Z configurations; the compounds of this invention include both configurations.
- alkynyl refers to straight or branched chain aliphatic hydrocarbon radicals containing 2 to 7 carbon atoms having at least one triple bond.
- phenyl refers to a group.
- substituted phenyl refers to a phenyl group that is substituted with the indicated substituents.
- aryl when used as such, refers to an aromatic carbocyclic group, having 6 to 10 carbon atoms including without limitation phenyl and napthyl.
- heteroaryl refers to a 5- or 6-membered aromatic cyclic group having at least one carbon atom and one or more oxygen, nitrogen or sulfur atoms in the ring, as for example furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, tetrazolyl, and the like, including all position isomers.
- Preferred heteroaryl groups include pyridine, thiazole and thiophene.
- cycloalkyl refers to a saturated hydrocarbon ring. Cycloalkyls can be monocyclic or can be fused, spiro or bridged bicyclic or tricyclic ring systems. Monocyclic cycloalkyl rings contain from 3 to 10 carbon atoms, preferably from 3 to 7 carbon atoms, as for example cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- Bicyclic and tricyclic cycloalkyl rings contain from 7 to 28 carbon atoms, preferably from 7 to 19 carbon atoms, in the ring system; and include, for example, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]cyclooctanyl, tricyclo[3.2.2.02,4]nonyl, and norbornyl, and bicyclo[3.2.2]nonyl.
- cycloalkenyl refers to an unsaturated hydrocarbon ring. Cycloalkenyl rings are non-aromatic and contain at least one (preferably only one) carbon-carbon double bond.
- Cycloalkenyl rings are monocyclic, or are fused, spiro or bridged bicyclic or tricyclic ring systems.
- Monocyclic cycloalkenyl rings contain from 5 to 10 carbon atoms, preferably from 5 to 7 carbon atoms, and include, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, and cyclohexenyl.
- Bicyclic and tricyclic cycloalkenyl rings contain from 7 to 28 carbon atoms in the ring, preferably from 7 to 19 carbon atoms, in the ring system; and include, for example, bicyclo[2.2.1]hept-2-ene, bicyclo[2.2.2]cyclooct-2-enyl, tricyclo[3.2.2.02,4]non-6-enyl, and bicyclo[3.2.2]non-6-enyl.
- amido refers to a radical or substituent of the formula —NR′′C( ⁇ O)R′′′, wherein R′′ and R′′′ represent hydrogen or alkyl.
- carboxylate refers to a radical or substituent of the formula —C( ⁇ O)—NR′′R′′′, wherein R′′ and R′′′ are as previously defined.
- sulfonamide refers to a radical or substituent of the formula —SO 2 NR′′R′′′ or —NR′′SO 2 R′′′, wherein R′′ and R′′′ are as previously defined.
- halogen refers to a radical or substituent selected from the group consisting of chloro, bromo, iodo, and fluoro.
- HPLC refers to high-performance liquid chromatography.
- “Substituted” is intended to indicate that one or more hydrogens on the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group(s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
- a substituent is an oxo ( ⁇ O) group, then 2 hydrogens on the atom are replaced.
- the compounds of the invention and their pharmaceutically acceptable salts are useful in treating and preventing viral infections and diseases in living hosts when used in combination with other active agents, including but not limited to interferons, ribavirin, immunoglobulins, immunomodulators, anti-inflammatory agents, antibiotics, antivirals, anti-infectious agents, and the like.
- Compounds described herein are also useful in preventing or resolving orthopox viral infections in cell, tissue or organ cultures and other in vitro applications.
- inclusion of compounds of the invention as a supplement in cell or tissue culture growth media and cell or tissue culture components will prevent viral infections or contaminations of cultures not previously infected with viruses.
- Compounds described above may also be used to eliminate or attenuate viral replication in cultures or other biological materials infected or contaminated with viruses (for example, blood), after a suitable treatment period, under any number of treatment conditions as determined by the skilled artisan.
- the compounds of the invention can form useful salts with inorganic and organic acids such as hydrochloric, sulfuric, acetic, lactic, or the like and with inorganic or organic bases such as sodium or potassium hydroxide, piperidine, ammonium hydroxide, or the like.
- inorganic and organic acids such as hydrochloric, sulfuric, acetic, lactic, or the like
- inorganic or organic bases such as sodium or potassium hydroxide, piperidine, ammonium hydroxide, or the like.
- the pharmaceutically acceptable salts of the compounds of Formula I are prepared following procedures that are familiar to those skilled in the art.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio.
- the compounds of the present invention may have at least one chiral center, the compounds may thus exist as enantiomers.
- the compounds of the present invention may also possess two or more chiral centers and thus may also exist as diastereomers or as exo or endo isomers.
- these isomers may be separated by conventional techniques such as preparative chromatography. Accordingly, the compounds may be prepared as a racemic mixture or, by either enantiospecific synthesis or resolution, as individual enantiomers.
- the compounds may, for example, be resolved from a racemic mixture into their component racemates by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as ( ⁇ )-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-1-tartaric acid followed by fractional crystallization and regeneration of the free base.
- the racemic mixture may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
- the compounds may be resolved using a chiral HPLC column. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
- the compounds of the present invention are useful for treating orthopoxvirus infection in living hosts, for example, mammals including humans. When administered to a living host the compounds can be used alone, or as a pharmaceutical composition.
- compositions comprising the compounds of the present invention, either alone or in combination with each other, offer a treatment against orthopoxvirus infection.
- the antiviral pharmaceutical compositions of the present invention comprise one or more of the compound(s) of Formula I above, as the active ingredient in combination with a pharmaceutically acceptable carrier medium or auxiliary agent.
- composition may be prepared in various forms for administration, including tablets, caplets, pills or dragees, or can be filled in suitable containers, such as capsules, or, in the case of suspensions, filled into bottles.
- pharmaceutically acceptable carrier medium includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- Gennaro (William and Wilkins, Baltimore, Md., 2000) discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the antiviral compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention.
- the active agent may be present in an amount of at least 0.5% and generally not more than 90% by weight, based on the total weight of the composition, including carrier medium and/or auxiliary agent(s), if any.
- the proportion of active agent varies between 5 to 50% by weight of the composition.
- compositions suitable for enteral or parenteral administration can be used to make up the composition.
- Gelatine, lactose, starch, magnesium stearate, talc, vegetable and animal fats and oils, gum, polyalkylene glycol, or other known medicament components may all be suitable as carrier media or excipients.
- the compounds of the invention may be administered using any amount and any route of administration effective for attenuating infectivity of the virus.
- amount effective to attenuate infectivity of virus refers to a nontoxic but sufficient amount of the antiviral agent to provide the desired prophylaxis and/or treatment of viral infection. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular antiviral agent, its mode of administration, and the like.
- the compounds of the invention are administered within 72 hours of symptom onset, more preferably within 48 hours of symptom onset, and most preferably within 24 hours of symptom onset.
- Symptoms of initial orthopoxvirus infections depend on the exact virus contracted.
- the initial symptoms of a smallpox infection include fever, malaise, head and body aches, and sometimes vomiting.
- the antiviral compounds are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
- dosage unit form refers to a physically discrete unit of antiviral agent appropriate for the patient to be treated.
- Each dosage should contain the quantity of active material calculated to produce the desired therapeutic effect either as such, or in association with the selected pharmaceutical carrier medium and/or the supplemental active agent(s), if any.
- the antiviral compounds of the invention will be administered in dosage units containing from about 10 mg to about 10,000 mg of the antiviral agent by weight of the composition, with a range of about 100 mg to about 2,000 mg being preferred.
- the compounds may be administered orally, rectally, parenterally, such as by intramuscular injection, subcutaneous injection, intravenous infusion or the like, intracisternally, intravaginally, intraperitoneally, locally, such as by powders, ointments, or drops, or the like, or by inhalation, such as by aerosol or the like, taking into account the nature and severity of the infection being treated.
- the compounds of the invention may be administered at dosage levels of about 0.125 to about 250 mg/kg of subject body weight per dose, one or more times a day, to obtain the desired therapeutic effect.
- the compounds of the invention will typically be administered from 1 to 4 times a day so as to deliver the above-mentioned daily dosage.
- the exact regimen for administration of the compounds and compositions described herein will necessarily be dependent on the needs of the individual host or patient being treated, the type of treatment administered and the judgment of the attending medical specialist.
- compounds of the invention are preferably administered within 14 days after possible exposure; more preferably within 7 days post exposure; and most preferably within 48 hours post exposure.
- the dosages may be essentially the same, whether for treatment or prophylaxis of virus infection.
- any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1999.
- the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- Example 2-14 The compounds of Examples 2-14 were synthesized following the above mentioned general procedure for Example 1 using compound 1(a) and reacting it with the following hydrazides: isonicotinic hydrazide, 4-bromobenzoic hydrazide, 3-bromobenzoic hydrazide, 3-chlorobenzoic hydrazide, 2-bromobenzoic hydrazide, 2-chlorobenzoic hydrazide, 4-chlorobenzoic hydrazide, nicotinic hydrazide, 2-picolinyl hydrazide, 4-methoxybenzoic hydrazide, 4-nitrobenzoic hydrazide, 4-fluorobenzoic hydrazide, and 3-fluorobenzoic hydrazide.
- hydrazides isonicotinic hydrazide, 4-bromobenzoic hydrazide, 3-bromobenzoic hydrazide, 3-chlorobenzo
- Virus stocks of Vaccinia virus were prepared in Vero cells infected at low multiplicity (0.01 plaque forming units (PFU)/cell) and harvested when cytopathic effects were complete (4+CPE). The samples were frozen and thawed and then sonicated to release cell-associated virus. The cell debris was removed by low-speed centrifugation, and the resulting virus suspension was stored in 1 mL aliquots at ⁇ 80° C. The PFU/mL of the virus suspension was quantified by standard plaque assay on Vero and BSC-40 cells.
- PFU plaque forming units
- Vero cell monolayers were seeded on to 96-well plates and infected with 2-fold serial dilutions of the vaccinia virus stock. At 3 days post-infection, the cultures were fixed with 5% glutaraldehyde and stained with 0.1% crystal violet. Virus-induced CPE was quantified spectrophometrically at OD 570 . From this analysis, a 1:800 dilution of vaccinia virus stock was chosen for use in the HTS assay. This amount of vaccinia virus represents a multiplicity of infection of approximately 0.1 PFU/cell.
- Vero cell monolayers were infected with 1:800 dilution of vaccinia virus stock.
- Each plate contained the following controls: quadruplicate virus-infected wells, quadruplicate uninfected cell wells and a dose response curve in duplicate for cidofovir (CDV) added at 300, 100, 30 and 10 DAM, or phosphonoacetic acid (PAA) added at 2100, 714, 210, and 71 ⁇ M as reference standards.
- CDV cidofovir
- PAA phosphonoacetic acid
- the S/N ratio ratio of signal of cell control wells (signal) to virus control wells (noise)
- the well-to-well and assay-to-assay variability was less than 20%.
- the EC 50 values for CDV and PAA were determined to be 84 ⁇ 15 ⁇ M and 985 ⁇ 85 ⁇ M, respectively. These values were within the range of published values for these compounds. Based on this analysis, the 1:800 dilution of vaccinia virus (boxed) was chosen for use in the assay.
- Representative compounds of the invention were tested in the vaccinia virus CPE assay. Compounds were dissolved in DMSO and diluted in medium such that the final concentration in each well was 5 ⁇ M compound and 0.5% DMSO. The compounds were added robotically to the culture medium using the Biomek® FX robot system. Following compound addition, the cultures were infected with vaccinia virus. After 3 days, plates were processed and CPE quantified as described.
- Representative compounds of the invention inhibited vaccinia virus-induced CPE by greater than 50% at the test concentration (5 ⁇ M). Selected compounds were further evaluated for potency (EC 50 ) in the CPE assay and cytotoxicity (CC 50 ) in an MTT assay.
- the MTT assay measures mitochondrial dehydrogenase activity in dividing cells. This method detects the in situ reduction of (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) using an electron coupling reagent (phenazine methosulfate) to produce an insoluble formazan.
- the absorbance of the formazan at 490 nm can be measured directly from 96-well assay plates following solubilization of the formazan in 50% ethanol. The quantity of formazan product is directly proportional to the number of living cells in culture.
- Table 4 lists EC50 values of select compounds of the invention measuring anti- orthopox virus activities in these CPE inhibition assays for cidofovir-resistant cowpox virus (Brighton Red strain, (available from USAMRIID Fort Detrick, Frederick, Md.), camelpox, and monkeypox virus (Zaire(V79-1-005-scab)).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 60/480,182, filed Jun. 20, 2003, which is incorporated by reference herein in its entirety.
- The present invention relates to the use of di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
- The Orthopox genus (Orthopoxviridae) is a member of the Poxviridae family and the Choropoxivirinae subfamily. The genus consists of numerous viruses that cause significant disease in human and animal populations. Viruses in the orthopox genus include cowpox, monkeypox, vaccina, and variola (smallpox), all of which can infect humans.
- The smallpox (variola) virus is of particular importance. Recent concerns over the use of smallpox virus as a biological weapon has underscored the necessity of developing small molecule therapeutics that target orthopoxviruses. Variola virus is highly transmissible and causes severe disease in humans resulting in high mortality rates (Henderson et al. (1999) JAMA. 281:2127-2137). Moreover, there is precedent for use of variola virus as a biological weapon. During the French and Indian wars (1754-1765), British soldiers distributed blankets used by smallpox patients to American Indians in order to establish epidemics (Stern, E. W. and Stern A. E. 1945. The effect of smallpox on the destiny of the Amerindian. Boston). The resulting outbreaks caused 50% mortality in some Indian tribes (Stern, E. W. and Stern A. E.). More recently, the Soviet government launched a program to produce highly virulent weaponized forms of variola in aerosolized suspensions (Henderson, supra). Of more concern is the observation that recombinant forms of poxvirus have been developed that have the potential of causing disease in vaccinated animals (Jackson et al. (2001) J. Virol., 75:1205-1210).
- The smallpox vaccine program was terminated in 1972; thus, many individuals are no longer immune to smallpox infection. Even vaccinated individuals may no longer be fully protected, especially against highly virulent or recombinant strains of virus (Downie and McCarthy. (1958) J Hyg. 56:479-487; Jackson, supra). Therefore, mortality rates would be high if variola virus were reintroduced into the human population either deliberately or accidentally.
- Variola virus is naturally transmitted via aerosolized droplets to the respiratory mucosa where replication in lymph tissue produces asymptomatic infection that lasts 1-3 days. Virus is disseminated through the lymph to the skin where replication in the small dermal blood vessels and subsequent infection and lysis of adjacent epidermal cells produces skin lesions (Moss, B. (1990) Poxyiridae and Their Replication, 2079-2111. In B. N. Fields and D. M. Knipe (eds.), Fields Virology. Raven Press, Ltd., New York). Two forms of disease are associated with variola virus infection; variola major, the most common form of disease, which produces a 30% mortality rate and variola minor, which is less prevalent and rarely leads to death (<1%). Mortality is the result of disseminated intravascular coagulation, hypotension, and cardiovascular collapse, that can be exacerbated by clotting defects in the rare hemorrhagic type of smallpox (Moss, supra).
- A recent outbreak of monkeypox virus underscores the need for developing small molecule therapeutics that target viruses in the orthpox genus. Appearance of monkeypox in the US represents an emerging infection. Monkeypox and smallpox cause similar diseases in humans, however mortality for monkeypox is lower (1%).
- Vaccination is the current means for preventing orthopox virus disease, particularly smallpox disease. The smallpox vaccine was developed using attenuated strains of vaccinia virus that replicate locally and provide protective immunity against variola virus in greater than 95% of vaccinated individuals (Modlin (2001) MMWR (Morb Mort Wkly Rep) 50:1-25). Adverse advents associated with vaccination occur frequently (1:5000) and include generalized vaccinia and inadvertent transfer of vaccinia from the vaccination site. More serious complications such as encephalitis occur at a rate of 1:300,000, which is often fatal (Modlin, supra). The risk of adverse events is even more pronounced in immunocompromised individuals (Engler et al. (2002) J Allergy Clin Immunol. 110:357-365). Thus, vaccination is contraindicated for people with AIDS or allergic skin diseases (Engler et al.). While protective immunity lasts for many years, the antibody response to smallpox vaccination is significantly reduced 10 to 15 years post inoculation (Downie, supra). In addition, vaccination may not be protective against recombinant forms of ortho poxvirus. A recent study showed that recombinant forms of mousepox virus that express IL-4 cause death in vaccinated mice (Jackson, supra). Given the side effects associated with vaccination, contraindication of immunocompromised individuals, and inability to protect against recombinant strains of virus, better preventatives and/or new therapeutics for treatment of smallpox virus infection are needed.
- Vaccinia virus immunoglobulin (VIG) has been used for the treatment of post-vaccination complications. VIG is an isotonic sterile solution of immunoglobulin fraction of plasma derived from individuals who received the vaccinia virus vaccine. It is used to treat eczema vaccinatum and some forms of progressive vaccinia. Since this product is available in limited quantities and difficult to obtain, it has not been indicated for use in the event of a generalized smallpox outbreak (Modlin, supra).
- Cidofovir ([(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] [HPMPC]) is a nucleoside analog approved for treatment of CMV retinitis in AIDS patients. Cidofovir has been shown to have activity in vitro against a number of DNA containing viruses including adenovirus, herpesviruses, hepadnaviruses, polyomaviruses, papillomaviruses, and ortho poxviruses (Bronson et al. (1990) Adv. Exp. Med. Biol. 278:277-83; De Clercq et al. (1987) Antiviral Res. 8:261-272; de Oliveira et al. (1996) Antiviral Res. 31:165-172; Snoeck et al. (2001) Clin Infect. Dis. 33:597-602). Cidofovir has also been found to inhibit authentic variola virus replication (Smee et al. (2002) Antimicrob. Agents Chemother. 46:1329-1335).
- However, cidofovir administration is associated with a number of issues. Cidofovir is poorly bioavailable and must be administered intravenously (Lalezari et al. (1997) Ann. Intern. Med. 126:257-263). Moreover, cidofovir produces dose-limiting nephrotoxicity upon intravenous administration (Lalezari et al.). In addition, cidofovir-resistance has been noted for multiple viruses. Cidofovir-resistant cowpox, monkeypox, vaccinia, and camelpox virus variants have been isolated in the laboratory by repeated passage in the presence of drug (Smee, supra). Cidofovir-resistance represents a significant limitation for use of this compound to treat orthopoxvirus replication. Thus, the poor bioavailability, need for intravenous administration, and prevalence of resistant virus underscores the need for development of additional and alternative therapies to treat orthopoxvirus infection.
- In addition to viral polymerase inhibitors such as cidofovir, a number of other compounds have been reported to inhibit orthopoxvirus replication (De Clercq. (2001) Clin Microbiol. Rev. 14:382-397). Historically, methisazone, the prototypical thiosemicarbazone, has been used in the prophylactic treatment of smallpox infections (Bauer et al. (1969) Am. J Epidemiol. 90:130-145). However, this compound class has not garnered much attention since the eradication of smallpox due to generally unacceptable side effects such as severe nausea and vomiting. Mechanism of action studies suggest that methisazone interferes with translation of L genes (De Clercq (2001), supra). Like cidofovir, methisazone is a relatively non-specific antiviral compound and can inhibit a number of other viruses including adenoviruses, picornaviruses, reoviruses, arboviruses, and myxoviruses (Id.).
- Another class of compounds potentially useful for the treatment of poxviruses is represented by inhibitors of S-adenosylhomocysteine hydrolase (SAH). This enzyme is responsible for the conversion of S-adenosylhomocysteine to adenosine and homocysteine, a necessary step in the methylation and maturation of viral mRNA. Inhibitors of this enzyme have shown efficacy at inhibiting vaccinia virus in vitro and in vivo (De Clercq et al. (1998) Nucleosides Nucleotides. 17:625-634.). Structurally, all active inhibitors reported to date are analogues of the nucleoside adenosine. Many are carbocyclic derivatives, exemplified by Neplanacin A and 3-Deazaneplanacin A. While these compounds have shown some efficacy in animal models, like many nucleoside analogues, they suffer from general toxicity and/or poor pharmacokinetic properties (Coulombe et al. (1995) Eur. J Drug Metab Pharmacokinet. 20:197-202; Obara et al. (1996) J Med. Chem. 39:3847-3852). It is unlikely that these compounds can be administered orally, and it is currently unclear whether they can act prophylactically against smallpox infections. Identification of non-nucleoside inhibitors of SAH hydrolase, and other chemically tractable variola virus genome targets that are orally bioavailable and possess desirable pharmicokinetic (PK) and absorption, distribution, metabolism, elimination (ADME) properties would be a significant improvement over the reported nucleoside analogues. In summary, currently available compounds that inhibit smallpox virus replication are generally non-specific and suffer from use limiting toxicities and/or questionable efficacies.
- In U.S. Pat. No. 6,433,016 (Aug. 13, 2002) and U.S. Application Publication 2002/0193443 A1 (published Dec. 19, 2002) a series of imidodisulfamide derivatives are described as being useful for orthopox virus infections.
- New therapies and preventatives are clearly needed for infections and diseases caused by orthopoxvirus infection.
- Several orthopoxviruses, including cowpox, monkeypox, camelpox, variola, and probably most other mammalian orthopoxviruses, can be grown readily in cell culture and produce robust cytopathic effect (CPE) in 3 to 5 days. Since this CPE is directly related to viral replication, compounds that inhibit virus replication in cell culture can be identified readily as conferring protection from virus-induced CPE (although it is theoretically possible to inhibit CPE without inhibiting virus replication). Moreover, compounds having identified activity against cowpox virus will also likely be active against human variola virus given the high degree of homology (>95%) between these two viruseshe replication proteins of orthopoxviruses are highly homologous. In general, the viruses diverge in regions of their genomes that encode immuno-modulatory functions (host-specific). Additionally, many compounds have been identified in the literature that inhibit orthopoxvirus replication in cell culture and there are few, if any, examples were a compound is dramatically more potent against a one species of orthopoxvirus and not the others
-
- wherein:
- R1 and R2 represent radicals independently selected from the group consisting of hydrogen and alkyl;
- R3 and R4 represent radicals independently selected from the group consisting of hydrogen and alky;
-
- R5 represents a radical selected from the group consisting of hydrogen and alkyl;
- R6 represents a radical selected from the group consisting of straight- or branched chain alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, cycloalkenyl, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group selected from the group consisting of furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, and tetrazolyl; a substituted or unsubstituted arylalkyl group, and a substituted or unsubstituted heteroarylalkyl group, wherein the heteroaryl is selected from the group consisting pyridine and thiophene;
-
- said aryl group substituents and said arylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- said heteroaryl group substituents and said heteroarylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, amino, monoalkylamino, dialkylamino, aminoalkyl, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- or a pharmaceutically acceptable salt thereof.
- The invention also relates to pharmaceutical compositions containing the antiviral compounds of Formula I and the corresponding methods of use for treating and preventing infections caused by orthopox viruses.
- In one aspect, the instant invention provides compounds of Formula I:
wherein R1, R2, R3, R4, R5, R6, and M are as defined above, with the proviso that said formula does include the compounds selected from the group consisting of N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-4-pyridinecarboxamide; 4-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 3-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 3-chloro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-4-pyridinecarboxamide; 4-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-methoxy-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethanocycloprop[f]isoindol-2(1H)-yl)-benzamide; 3-bromo-N-(1′,3′,3′a,4′,7′,7′a-hexahydro-1′,3′-dioxospiro[cyclopropane-1,8′-[4,7]methano[2H]isoindol]-2′-yl)-benzamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-tricyclo[3.3.1.13,7]decane-1-carboxamide and 4-Bromo-N-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)-benzamide. -
- R6 represents a radical selected from the group consisting of straight- or branched chain allyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, cycloalkenyl, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group selected from the group consisting of furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, and tetrazolyl; a substituted or unsubstituted arylalkyl group, and a substituted or unsubstituted heteroarylalkyl group, wherein the heteroaryl is selected from the group consisting pyridine and thiophene;
- said aryl group substituents and said arylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- said heteroaryl group substituents and said heteroarylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, amino, monoalkylamino, dialkylamino, aminoalkyl, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- or a pharmaceutically acceptable salt thereof.
-
- R6 represents a radical selected from the group consisting of straight- or branched chain alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, cycloalkenyl, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group selected from the group consisting of furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, and tetrazolyl; a substituted or unsubstituted arylalkyl group, and a substituted or unsubstituted heteroarylalkyl group, wherein the heteroaryl is selected from the group consisting pyridine and thiophene;
- said aryl group substituents and said arylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- said heteroaryl group substituents and said heteroarylalkyl group substituents being one or more radical(s) independently selected from the group consisting of a straight- or branched chain alkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, halogen, polyfluoroalkyl, polyfluoroalkoxy, carboxy, cyano, amino, monoalkylamino, dialkylamino, aminoalkyl, nitro, amido, amidoalkyl, carboxamide, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, and mercapto;
- or a pharmaceutically acceptable salt thereof.
- Preferred compounds of the invention include 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethanocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-bromo-N-(octahydro-1,3-dioxo-2H-isoindol-2-yl)-benzamide; 4-fluoro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 3-fluoro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-4-pyridinecarboxamide; 4-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-chloro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-trifluoromethyl-N-bicyclo[2.2.2]oct-5-ene-2,3-dicarboximido-benzamide; 4-trifluoromethyl-N-bicyclo[2.2.2]octane-2,3-dicarboximido-benzamide; and 2,4-dimethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-thiazole-5-carboxamide.
- Another aspect of the invention includes the compounds selected from the group consisting of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 2-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-3-pyridinecarboxamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-2-pyridinecarboxamide; 4-nitro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-fluoro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 3-fluoro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethanocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-bromo-N-(1,3-(2H,3aH)-dioxo-4,8-ethenocyclohepta[c]pyrrolyl)-benzamide; 4-bromo-N-(octahydro-1,3-dioxo-2H-isoindol-2-yl)-benzamide; 4-bromo-N-bicyclo[2.2.2]oct-5-ene-2,3-dicarboximido-benzamide; 4-bromo-N-bicyclo[2.2.2]octane-2,3-dicarboximido-benzamide; 4-cyano-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4 trifluoromethyl-N-bicyclo[2.2.2]oct-5-ene-2,3-dicarboximido-benzamide; and 4-trifluoromethyl-N-bicyclo[2.2.2]octane-2,3-dicarboximido-benzamide.
- In further embodiments of the compound of this invention, the compound may be selected from any of the compounds described, supra.
- The present invention provides a method for preventing and treating orthopoxvirus infections and for preventing and treating diseases associated with such infections in a living host (for example, a mammal including a human) having or susceptible to an orthopoxvirus infection, comprising the step of administering to the living host a therapeutically effective amount of a compound of the formula:
- wherein R1, R2, R3, R4, R5, R6, and M are as defined for compounds of Formula I above, or a pharmaceutically acceptable salt to a host susceptible to, or suffering from such infection.
- A preferred method includes the prevention and treatment of orthopoxvirus infections and diseases associated with such infections in a living host having or susceptible to an orthopoxvirus infection, comprising the step of administering a therapeutically effective amount of the compounds of the Formula Ia, above, or a pharmaceutically acceptable salt thereof. Another preferred method includes the prophylaxis or treatment of orthopoxvirus infections and diseases associated with such infections in a living host having or susceptible to an orthopoxvirus infection, comprising the step of administering a therapeutically effective amount of the compounds of the Formula Ib, above or a pharmaceutically acceptable salt, thereof.
- The present invention additionally provides methods for the treatment or prevention of infections caused by an orthopox virus wherein the orthopox virus is selected from the group consisting of vaccinia virus, cowpox virus, smallpox (variola) virus, monkeypox virus and camelpox virus; in a living host (for example, a mammal including a human) comprising the step of administering a therapeutically effective amount of the compounds of the invention to a host susceptible to, or suffering from such infection.
- In accordance with another aspect, the present invention provides a pharmaceutical composition for the treatment or prevention of orthopoxvirus infections and diseases associated with such infections in a living host, that comprises a therapeutically effective amount of one or more of the compounds of the formula:
- wherein R1, R2, R3, R4, R5, R6, and M are as defined for compounds of Formula I above, and a pharmaceutically acceptable carrier medium.
- The compounds of the invention described herein, their isomers and pharmaceutically acceptable salts exhibit antiviral activity. The compounds of the invention are particularly effective against orthopoxviruses, and are useful in the prophylaxis and/or treatment of infections and diseases associated with this virus in living hosts. Examples of orthopoxviruses that may be treated or prevented according to this invention include, but are not limited to, aractuba virus, BeAn 58058 virus, buffalopox virus, camelpox virus (such as Camelpox virus 903, Camelpox virus CMG, Camelpox virus CMS, Camelpox virus CP1, Camelpox virus CP5, and Camelpox virus M-96), cantagalo orthopoxvirus, cowpox virus (such as Cowpox virus strain Hamburg-1985 and Cowpox virus strain Turkmenia-1974), Ectromelia virus (such as Belo Horizonte virus), elephantpox virus, monkeypox virus (such as Monkeypox virus strain Sierra Leone 70-0266 and Monkeypox virus strain Zaire 77-0666), rabbitpox virus (such as Rabbitpox strain Utrecht), raccoonpox virus, skunkpox virus, taterapox virus, vaccinia virus (including, but not limited to, the following strains: strain Ankara, strain Copenhagan, strain Dairen I, strain IHD-J, strain L-IPV, strain LC16M8, strain LC16MO, strain Lister, strain LIVP, strain Tian Tan, strain WR 65-16, strain WR, and strain Wyeth), Variola virus (such as variola major virus and variola minor virus), and volepox virus.
- In vitro cell-based studies have been performed that demonstrate the usefulness of compounds described herein as antiviral agents. For example, antiviral activity of representative compounds was evaluated in assays that measure the ability of compounds to protect cells from virus-induced CPE. Cells that will support growth of the particular orthopox virus strain are seeded into 96-well tissue culture treated plates and then infected with an amount of the appropriate orthopox virus strain that results in complete CPE in ˜3 days. Various dilutions of inhibitory compound(s) are added and the plates are incubated at the appropriate temperature for optimal virus growth. At the end of the incubation period, cells are fixed with glutaraldehyde and stained with crystal violet. Cell protection is measured spectrophotometrically at OD570 nm. The interpolated compound dilution that results in 50% protection of the cell monolayer from virus-induced CPE is calculated and reported as the 50% effective concentration or EC50. Antiviral activity of representative compounds described herein occurred at drug concentrations that had no demonstrable effect on cell growth, indicating that the compounds were working specifically by an antiviral mechanism.
- As used herein, the term “compounds of the invention” means, collectively, the compounds of Formula I, pharmaceutically acceptable salts thereof, their isomers, and mixtures thereof. The compounds of the invention are identified herein by their chemical structure and/or chemical name. Where a compound is referred to by both a chemical structure and a chemical name, and that chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.
- The term “living host” as used herein refers to an organism that is living and capable of being infected with a virus, such as an orthopoxvirus; for example, a mammal, which includes a human.
- The term “alkyl” as used herein refers to straight or branched chain aliphatic hydrocarbon radicals of up to 10 carbon atoms, preferably up to 6 carbon atoms and more preferably 1 to 4 carbon atoms. Similarly, the term “alkyl”, or any variation thereof, used in combination form to name substituents, such as alkoxy (—O-alkyl), allylthio (—S-alkyl), monoalkylamino (—NH-alkyl), dialkylamino, (—N-(alkyl)alkyl), alkylsulfonyl (—S(O)2-alkyl), carboxyalkyl (-alkyl-COOH), or the like, also refers to aliphatic hydrocarbon radicals of one to six carbon atoms, and preferably of one to four carbon atoms. Also “alk” in structural formula denotes an alkyl group, unless divalency is indicated in which case the “alk” denotes the corresponding alkylene group(s). Additionally, the term “lower alkyl” denotes an alkyl group having one to four carbon atoms.
- The term “alkenyl” as used herein refers to straight or branched chain aliphatic hydrocarbon radicals of 2 to 7 carbon atoms containing one double bond. Such alkenyl moieties may exist in the E or Z configurations; the compounds of this invention include both configurations. The term “alkynyl” as used herein refers to straight or branched chain aliphatic hydrocarbon radicals containing 2 to 7 carbon atoms having at least one triple bond.
-
- As used herein, the term “aryl”, when used as such, refers to an aromatic carbocyclic group, having 6 to 10 carbon atoms including without limitation phenyl and napthyl.
- The term “heteroaryl,” as used herein, refers to a 5- or 6-membered aromatic cyclic group having at least one carbon atom and one or more oxygen, nitrogen or sulfur atoms in the ring, as for example furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, tetrazolyl, and the like, including all position isomers. Preferred heteroaryl groups include pyridine, thiazole and thiophene.
- As used herein, the term “cycloalkyl” refers to a saturated hydrocarbon ring. Cycloalkyls can be monocyclic or can be fused, spiro or bridged bicyclic or tricyclic ring systems. Monocyclic cycloalkyl rings contain from 3 to 10 carbon atoms, preferably from 3 to 7 carbon atoms, as for example cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Bicyclic and tricyclic cycloalkyl rings contain from 7 to 28 carbon atoms, preferably from 7 to 19 carbon atoms, in the ring system; and include, for example, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]cyclooctanyl, tricyclo[3.2.2.02,4]nonyl, and norbornyl, and bicyclo[3.2.2]nonyl. As used herein, the term “cycloalkenyl” refers to an unsaturated hydrocarbon ring. Cycloalkenyl rings are non-aromatic and contain at least one (preferably only one) carbon-carbon double bond. Cycloalkenyl rings are monocyclic, or are fused, spiro or bridged bicyclic or tricyclic ring systems. Monocyclic cycloalkenyl rings contain from 5 to 10 carbon atoms, preferably from 5 to 7 carbon atoms, and include, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, and cyclohexenyl. Bicyclic and tricyclic cycloalkenyl rings contain from 7 to 28 carbon atoms in the ring, preferably from 7 to 19 carbon atoms, in the ring system; and include, for example, bicyclo[2.2.1]hept-2-ene, bicyclo[2.2.2]cyclooct-2-enyl, tricyclo[3.2.2.02,4]non-6-enyl, and bicyclo[3.2.2]non-6-enyl.
- The term “amido,” as used herein, refers to a radical or substituent of the formula —NR″C(═O)R′″, wherein R″ and R′″ represent hydrogen or alkyl.
- The term “carboxamide,” as used herein, refers to a radical or substituent of the formula —C(═O)—NR″R′″, wherein R″ and R′″ are as previously defined.
- The term “sulfonamide,” as used herein, refers to a radical or substituent of the formula —SO2NR″R′″ or —NR″SO2R′″, wherein R″ and R′″ are as previously defined.
- The term “halogen,” as used herein, refers to a radical or substituent selected from the group consisting of chloro, bromo, iodo, and fluoro.
- The term “HPLC,” as used herein, refers to high-performance liquid chromatography.
- “Substituted” is intended to indicate that one or more hydrogens on the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group(s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is an oxo (═O) group, then 2 hydrogens on the atom are replaced.
- The compounds of the invention and their pharmaceutically acceptable salts are useful in treating and preventing viral infections and diseases in living hosts when used in combination with other active agents, including but not limited to interferons, ribavirin, immunoglobulins, immunomodulators, anti-inflammatory agents, antibiotics, antivirals, anti-infectious agents, and the like.
- Compounds described herein are also useful in preventing or resolving orthopox viral infections in cell, tissue or organ cultures and other in vitro applications. For example, inclusion of compounds of the invention as a supplement in cell or tissue culture growth media and cell or tissue culture components will prevent viral infections or contaminations of cultures not previously infected with viruses. Compounds described above may also be used to eliminate or attenuate viral replication in cultures or other biological materials infected or contaminated with viruses (for example, blood), after a suitable treatment period, under any number of treatment conditions as determined by the skilled artisan.
- The compounds of the invention can form useful salts with inorganic and organic acids such as hydrochloric, sulfuric, acetic, lactic, or the like and with inorganic or organic bases such as sodium or potassium hydroxide, piperidine, ammonium hydroxide, or the like. The pharmaceutically acceptable salts of the compounds of Formula I are prepared following procedures that are familiar to those skilled in the art.
- The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio.
- To the extent that certain compounds of the present invention may have at least one chiral center, the compounds may thus exist as enantiomers. In addition, the compounds of the present invention may also possess two or more chiral centers and thus may also exist as diastereomers or as exo or endo isomers. Where the processes for the preparation of the present compounds give rise to a mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. Accordingly, the compounds may be prepared as a racemic mixture or, by either enantiospecific synthesis or resolution, as individual enantiomers. The compounds may, for example, be resolved from a racemic mixture into their component racemates by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (−)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-1-tartaric acid followed by fractional crystallization and regeneration of the free base. The racemic mixture may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
- The compounds of the present invention are useful for treating orthopoxvirus infection in living hosts, for example, mammals including humans. When administered to a living host the compounds can be used alone, or as a pharmaceutical composition.
- Pharmaceutical compositions comprising the compounds of the present invention, either alone or in combination with each other, offer a treatment against orthopoxvirus infection. The antiviral pharmaceutical compositions of the present invention comprise one or more of the compound(s) of Formula I above, as the active ingredient in combination with a pharmaceutically acceptable carrier medium or auxiliary agent.
- The composition may be prepared in various forms for administration, including tablets, caplets, pills or dragees, or can be filled in suitable containers, such as capsules, or, in the case of suspensions, filled into bottles. As used herein, “pharmaceutically acceptable carrier medium” includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Twentieth Edition, A. R. Gennaro (William and Wilkins, Baltimore, Md., 2000) discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the antiviral compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention.
- In the pharmaceutical compositions of the invention, the active agent may be present in an amount of at least 0.5% and generally not more than 90% by weight, based on the total weight of the composition, including carrier medium and/or auxiliary agent(s), if any. Preferably, the proportion of active agent varies between 5 to 50% by weight of the composition.
- Pharmaceutical organic or inorganic solid or liquid carrier media suitable for enteral or parenteral administration can be used to make up the composition. Gelatine, lactose, starch, magnesium stearate, talc, vegetable and animal fats and oils, gum, polyalkylene glycol, or other known medicament components may all be suitable as carrier media or excipients.
- The compounds of the invention may be administered using any amount and any route of administration effective for attenuating infectivity of the virus. Thus, the expression “amount effective to attenuate infectivity of virus,” as used herein, refers to a nontoxic but sufficient amount of the antiviral agent to provide the desired prophylaxis and/or treatment of viral infection. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular antiviral agent, its mode of administration, and the like.
- Preferably the compounds of the invention are administered within 72 hours of symptom onset, more preferably within 48 hours of symptom onset, and most preferably within 24 hours of symptom onset. Symptoms of initial orthopoxvirus infections depend on the exact virus contracted. For example, the initial symptoms of a smallpox infection include fever, malaise, head and body aches, and sometimes vomiting.
- The antiviral compounds are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. “Dosage unit form,” as used herein, refers to a physically discrete unit of antiviral agent appropriate for the patient to be treated. Each dosage should contain the quantity of active material calculated to produce the desired therapeutic effect either as such, or in association with the selected pharmaceutical carrier medium and/or the supplemental active agent(s), if any. Typically, the antiviral compounds of the invention will be administered in dosage units containing from about 10 mg to about 10,000 mg of the antiviral agent by weight of the composition, with a range of about 100 mg to about 2,000 mg being preferred.
- The compounds may be administered orally, rectally, parenterally, such as by intramuscular injection, subcutaneous injection, intravenous infusion or the like, intracisternally, intravaginally, intraperitoneally, locally, such as by powders, ointments, or drops, or the like, or by inhalation, such as by aerosol or the like, taking into account the nature and severity of the infection being treated. Depending on the route of administration, the compounds of the invention may be administered at dosage levels of about 0.125 to about 250 mg/kg of subject body weight per dose, one or more times a day, to obtain the desired therapeutic effect.
- The compounds of the invention will typically be administered from 1 to 4 times a day so as to deliver the above-mentioned daily dosage. However, the exact regimen for administration of the compounds and compositions described herein will necessarily be dependent on the needs of the individual host or patient being treated, the type of treatment administered and the judgment of the attending medical specialist.
- For prophylaxis treatment, compounds of the invention are preferably administered within 14 days after possible exposure; more preferably within 7 days post exposure; and most preferably within 48 hours post exposure. The dosages may be essentially the same, whether for treatment or prophylaxis of virus infection.
- During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- The following examples are provided to describe the invention in further detail. These examples illustrate suitable methods of synthesis of representative compounds of this invention. However, the methods of synthesis are intended to illustrate and not to limit the invention to those exemplified below. The starting materials for preparing the compounds of the invention are either commercially available or can be conveniently prepared according to one of the examples set forth below or otherwise using known chemistry procedures.
-
- A mixture of cycloheptatriene (5 g, 54.26 mmol) and maleic anhydride (6.13 g, 62.40 mmol) in xylenes (35 mL) was heated at reflux under argon overnight. The reaction was cooled to room temperature and a tan precipitate was collected by filtration and dried to give 2.94 grams (28%) of the desired product.
- b. Preparation of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide. A mixture of compound 1(a) (150 mg, 0.788 mmol) and 4-trifloromethylbenzhydrazide (169 mg, 0.827 mmol) in ethanol (10 mL) was heated under argon overnight. The solvent was removed by rotary evaporation. Purification by column chromatography on silica gel using 1/1 hexane/ethyl acetate provided 152 mg (51%) of the product as a white solid.
- The compounds of Examples 2-14 were synthesized following the above mentioned general procedure for Example 1 using compound 1(a) and reacting it with the following hydrazides: isonicotinic hydrazide, 4-bromobenzoic hydrazide, 3-bromobenzoic hydrazide, 3-chlorobenzoic hydrazide, 2-bromobenzoic hydrazide, 2-chlorobenzoic hydrazide, 4-chlorobenzoic hydrazide, nicotinic hydrazide, 2-picolinyl hydrazide, 4-methoxybenzoic hydrazide, 4-nitrobenzoic hydrazide, 4-fluorobenzoic hydrazide, and 3-fluorobenzoic hydrazide.
-
- To a solution of compound 1(a) (1 g, 5.26 mmol) in ethanol (20 mL) was added 10% palladium on activated carbon (100 mg, 10 wt %). The mixture was shaken on a Parr hydrogenator under an atmosphere of hydrogen at 50 psi for 3 hours. The mixture was filtered through a micron filter to remove the palladium, and the filtrate was concentrated to give 384 mg (38%) of the product as a white solid.
- b. Preparation of 4-bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethanocycloprop[f]isoindol-2(1H)-yl)-benzamide. A mixture of compound 15(a) (350 mg, 1.82 mmol) and 4-bromobenzoic hydrazide (411 mg, 1.91 mmol) in ethanol (10 mL) was heated under argon for 48 hours. The solvent was removed by rotary evaporation. Purification by column chromatography on silica gel using 1/1 hexane/ethyl acetate as eluent provided 444 mg (63%) of the product as a white solid.
-
- A mixture of 1,3-cycloheptadiene (0.87 mL, 10.62 mmol) and maleic anhydride (1.2 g, 12.24 mmol) in xylenes (7 mL) was heated at reflux under argon overnight. The reaction was cooled to room temperature, and a tan precipitate was collected by filtration and dried to give 1.59 grams (78%) of the desired product.
- b. Preparation of 4-bromo-N-(1,3-(2H,3aH)-dioxo-4,8-ethenocyclohepta[c]pyrrolyl)-benzamide. A mixture of compound 16(a) (500 mg, 2.6 mmol) and 4-bromobenzoic hydrazide (587 mg, 2.73 mmol) in ethanol (5 mL) was heated under argon overnight. The solvent was removed by rotary evaporation. Purification by column chromatography on silica gel using 1/1 hexane/ethyl acetate provided 683 mg (67%) of the product as a white solid.
- A mixture of cis-cyclohexanedicarboxylic anhydride (150 mg, 0.97 mmol) and 4-bromobenzoic hydrazide (220 mg, 1.02 mmol) in ethanol (10 mL) was heated under argon overnight. The solvent was removed via rotary evaporation. Purification by column chromatography on silica gel using 1/1 hexane/ethyl acetate as eluent provided 179 mg (52%) of the desired product as a white solid.
-
- A mixture of 1,3-cyclohexadiene (2.4 mL, 24.96 mmol) and maleic anhydride (2.81 g, 28.66 mmol) in xylenes (15 mL) was heated at relux overnight. The solution was cooled to room temperature and the precipitate was collected by suction filtration. The solid was washed with xylenes and dried to give 3.08 g (69%) of the product as a tan solid.
- b. Preparation of compound 4-bromo-N-bicyclo[2.2.2]oct-5-ene-2,3-dicarboximido-benzamide. A mixture of compound 18(a) (150 mg, 0.84 mmol) and 4-bromobenzoic hydrazide (190 mg, 0.88 mmol) in ethanol (10 mL) was heated under argon overnight. The solvent was removed by rotary evaporation. Purification by column chromatography on silica gel using 1/1 hexane/ethyl acetate gave 210 mg (67%) of the product as a white solid.
- A mixture of compound 1(a)(150 mg, 0.788 mmol) and 2,4-dimethylthiazole-5-carboxylic acid hydrazide (141 mg, 0.827 mmol) in ethanol (10 mL) was heated at reflux under argon overnight. The solution was then cooled to room temperature, and the white precipitate was collected by filtration. The solid was washed with ethanol, and air-dried affording 183 mg (68%) of the product as a white solid.
- By appropriate selection of suitable starting materials, other compounds of the invention may be prepared according to the procedures described in the foregoing examples. Representative examples of further di, tri, and tetracyclic acylhydrazide derivatives and analogues are set forth in Tables 1 and 2 below.
TABLE 1 Example **Mass Number R6 *NMR Spec Name 1. 1H NMR in DMSO-d6: δ 11.35(d, 1H); 11.09 (d, 1H); 8.08(d, 2H); 7.92(d, 2H); 5.799(s, 2H); 3.29(brs, 4H); 1.17(m, 2H); 0.26(m, 1H); 0.078(s, 1H) 375 (M − H)− 4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a- #octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 2. 1H NMR in DMSO-d6: δ 11.41(brs); 11.15 (brs); 8.77(d of d, 2H); 7.75(d, 2H); 5.77(brs, 2H); 3.27(brs, 4H); 1.15(brs, 2H); 0.25(m, 1H); 0.03(brs, 1H) 308 (M − H)− N-(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- #ethenocycloprop[f]isoindol- 2(1H)-yl)-4- pyridinecarboxamide 3. *** 385 (M − H)− 4-Bromo-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 4. 1H NMR in DMSO-d6: δ 11.13(brd, 1H); 10.89(brd, 1H); 7.99 (s, 1H); 7.82-7.76(m, 2H); 7.43(t, 1H); 5.72 (s, 2H); 3.22-3.08(m, 4H); 1.19(brs, 2H); 0.21(m, 1H); 0.17(brs, 1H) 385 (M − H)− 3-Bromo-N- #(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- #ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 5. 1H NMR in DMSO-d6: δ 11.21(brd, 1H); 10.98(brd, 1H); 7.92 (s, 1H), 7.85(d, 1H); 7.71(d, 1H); 7.58(t, 1H); 5.79(brs, 2H); 3.29-3.15(m, 4H) 1.19-1.15(m, 2H); 0.26 (m, 1H); 0.10(brs, 1H) 341 (M − H)− 3-Chloro-N- #(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 6. 1H NMR in CDCl3: δ 7.74(s, 1H); 7.69(d, 1H); 7.63(d, 1H); 7.41-7.31(m, 2H); 5.84(m, 2H); 3.48(m, 2H); 3.14 (s, 2H); 1.19(m, 2H); 0.38-0.20(m, 2H) 385 (M − H)− 2-Bromo-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- #ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 7. 1H NMR in CDCl3: δ 7.96(s, 1H); 7.83(d, 1H); 7.45(m, 2H); 7.36 (m, 1H); 5.86(d, 2H); 3.47(brs, 2H); 3.15(s, 2H); 1.15(brs, 2H); 0.39-0.20(m, 2H) 341 (M − H)− 2-Chloro-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- #ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 8. 1H NMR in DMSO-d6: δ 11.16(brd, 1H); 10.91(brd, 1H); 7.90 (d, 2H); 7.61(d, 2H); 5.79(s, 2H); 3.28(m, 4H); 1.17(s, 2H); 0.26 (m, 1H); 0.07(s, 1H) 341 (M − H)− 4-Chloro-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- #ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 9. 1H NMR in DMSO-d6: δ 11.33(brd, 1H); 11.06(brd, 1H); 9.04 (s, 1H); 8.8(m, 1H); 8.23(d, 1H); 7.56(m, 1H); 5.80(s, 2H); 3.29 (m, 4H); 1.17(m, 2H); 0.27(m, 1H); 0.07(s, 1H) 308 (M − H)− N-(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- # ethenocycloprop[f]isoindol- 2(1H)-yl)-3- pyridinecarboxamide 10. 1H NMR in DMSO-d6: δ 11.11(s, 1H); 8.70(d, 1H); 8.07-8.02(M, 2H); 7.7-7.66(m, 1H); 5.75 (m, 2H); 3.295(s, 4H) 1.16(m, 2H); 0.27(m, 1H); 0.10(s, 1H) 308 (M − H)− N-(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- #ethenocycloprop[f]isoindol- 2(1H)-yl)-2- pyridinecarboxamide 11. 1H NMR in DMSO-d6: δ 10.87(brd, 1H); 10.61(brd, 1H); 7.87 (d, 2H); 7.05(d, 2H); 5.78(br, 2H); 3.84(s, 3H); 3.30(s, 4H); 1.16 (m, 2H); 0.25(m, 1H); 0.07(brs, 1H) 339 (M + H)+ 4-Methoxy-N- #(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 12. 1H NMR in DMSO-d6: δ 11.537-11.469(brd, 1H); 8.38(d, 2H); 8.12 (d, 2H); 5.80(s, 2H); 3.3(br, 4H); 1.18(s, 2H); 0.27(m, 1H); 0.08 (s, 1H) 352 (M − H)− 4-Nitro-N- (3,3a,4,4a,5,5a,6,6a- #octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 13. 1H NMR in DMSO-d6: δ 11.04(br, 1H); 7.96 (s, 2H); 7.367(t, 2H); 5.791(s, 2H); 3.258 (4H & H2O); 1.18(d, 2H); 0.28(m, 1H); 0.09 (s, 1H) 327.0 (M + H)+ 4-Fluoro-N- (3,3a,4,4a,5,5a,6,6a- #octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 14. 1H NMR in DMSO-d6: δ 11.176(br, 1H); 7.768-7.459(m, 4H); 5.797(s, 2H); 3.293 (H2O & 4H); 1.174(s, 2H); 0.23(m, 1H); 0.05 (s, 1H) 327.0 (M + H)+ 3-Fluoro-N- (3,3a,4,4a,5,5a,6,6a- #octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 15. *** 388.9 (M − H)− 4-Bromo-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- ethanocycloprop[f]isoindol- 2(1H)-yl)-benzamide 16. 1H NMR in DMSO-d6: δ 11.14(brd, 1H); 7.85 (brd, 2H); 7.76(d, 2H); 6.10(brs, 2H); 3.43 (brd, 2H); 2.86(brs, 2H); 1.98-1.54(m, 6H) 387 (M − H)− 4-Bromo-N-(1,3-(2H, 3aH)- dioxo-4,8- ethenocyclohepta[c]pyrrolyl)- benzamide 17. 1H NMR in DMSO-d6: δ 11.16(s, 1H); 7.86 (d, 2H); 7.78(d, 2H); 3.14(brs, 2H); 1.81-1.68(brm, 4H); 1.42 (br, 4H) 350.9 (M + H)+ 4-Bromo-N-(octahydro-1,3- dioxo-2H-isoindol-2-yl)- benzamide 18. 1H NMR in DMSO-d6: δ 11.055(brd, 1H); 7.83(d, 2H); 7.76(d, 2H); 6.21(s, 2H); 3.15 (s, 2H); 3.04(s, 2H); 1.66(d, 2H); 1.28(d, 2H) 373 (M − H)− 4-Bromo-N- bicyclo[2.2.2]oct-5-ene-2,3- dicarboximido-benzamide 19. 1H NMR in DMSO-d6: δ 11.15(s, 1H); 7.87(d, 2H); 7.78(d, 2H); 3.07 (m, 2H); 2.04(s, 2H); 1.75-1.64(m, 5); 1.45-1.38(m, 3H) 377 (M + H)+ 4-Bromo-N- bicyclo[2.2.2]octane-2,3- dicarboximido-benzamide 20. 1H NMR in DMSO-d6: δ 11.36(br, 1H); 8.03 (s, 4H); 5.79(s, 2H); 3.30(4H+H2O); 2.50 (s, 2H); 1.20(s, 2H) 332.1 (M − H)− 4-Cyano-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- #2(1H)-yl)-benzamide 21. 1H NMR in DMSO-d6: δ 11.286(br, 1H); 8.13 (d, 2H); 8.10(d, 2H); 3.30(4H+H2O); 1.49-1.12(m, 4H); 0.83(s, 1H); 0.57(s, 1H) 377.0 (M − H)− 4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- #ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 22. *** *** 4-Methyl-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide 23. *** *** 3-Bromo-N- (1′,3′,3′a,4′,7′,7′a-hexahydro- 1′,3′- dioxospiro[cyclopropane- 1,8′- [4,7]methano[2H]isoindol]- 2′-yl)-benzamide 24. *** *** N-(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)- Tricyclo[3.3.1.13,7]decane- 1-carboxamide 25. *** *** N-(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzeneacetamide 26. *** *** 4-Bromo-N-(1,3,3a,4,7,7a- hexahydro-1,3-dioxo-4,7- methano-2H-isoindol-2-yl)- benzamide 27. *** *** 2,4-Dichloro-N- (1,3,3a,4,7,7a-hexahydro- 1,3-dioxo-4,7-methano-2H- isoindol-2-yl)-benzamide 28. 1H NMR in DMSO-d6: δ 11.37(br, 1H); 8.10 (d, 2H); 7.94(d, 2H); 6.22(s, 2H); 3.17(s, 2H); 3.05(s, 2H); 1.66 (m, 2H); 1.29(m, 2H) 365.0 (M + H)+ 4-Trifluoromethyl-N- bicyclo[2.2.2]oct-5-ene-2,3- dicarboximido-benzamide 29. 1H NMR in DMSO-d6: δ 11.33(s, 1H); 8.14(d, 2H); 8.11(d, 2H); 3.29 (s, 4H); 2.05(s, 2H); 1.76-1.65(m, 4H); 1.42 (s, 2H) 367.0 (M + H)+ 4-Trifluoromethyl-N- bicyclo[2.2.2]octane-2,3- dicarboximido-benzamide
*All 1H NMR and 13C NMR spectra were acquired on a Varian Mercury VX 300 Spectrometer and referenced to tetramethylsilane (TMS) unless indicated otherwise. Chemical shifts and coupling constants are reported in parts per million (ppm) and Hertz (Hz), respectively. Multiplicities indicated are: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, and br indicates a broad signal.
**Mass Spectroscopy data is expressed as a mass to charge ratio (m/z) for either (M + 1) or (M − 1) molecular ion.
***Indicates that data was not collected.
- The following table contains further examples of compounds of the invention, which may be prepared as exemplified above and/or may be synthesized according to the previous procedures or otherwise using conventional chemistry knowledge.
TABLE 2 Ex- am- ple Num- ber Structure Name 30. 4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo- 4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-N- methylbenzamide 31. 4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo- 4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-N- ethylbenzamide 32. 4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo- 7,8-dimethyl-4,6- ethenocycloprop[f]isoindol-2(1H)-yl)- benzamide 33. 4-Trifluoromethyl-N- (3a,4,7,7a,tetrahydro- 4,7-etheno-1H- isoindol-2(1H)-yl)- benzamide 34. N-(3,3a,4,4a,5,5a,6, 6a-octahydro-1,3- dioxo-7,8-dimethyl- 4,6-ethenocycloprop[f]isoindol-2(1H)-yl)- acetamide 35. N-(3,3a,4,4a,5,5a,6, 6a-octahydro-1,3- dioxo-7,8-dimethyl- 4,6-ethenocycloprop[f]isoindol-2(1H)-yl)- but-3-enamide 36. N-(3,3a,4,4a,5,5a,6, 6a-octahydro-1,3- dioxo-7,8-dimethyl- 4,6-ethenocycloprop[f]isoindol-2(1H)-yl)- cyclohexanecarbox- amide 37. 4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo- 7,8-dimethyl-4,6- ethenocycloprop[f]isoindol-2(1H)-yl)- benzylacetamide 38. 4-Pyridyl-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo- 7,8-dimethyl-4,6- ethenocycloprop[f]isoindol-2(1H)-yl)- acetamide 39. 3-Thienyl-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo- 7,8-dimethyl-4,6- ethenocycloprop[f]isoindol-2(1H)-yl)- acetamide 40. 41. 2,4-Dimethyl-N- (3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo- 4,6-ethenocycloprop[f]isoindol-2(1H)-yl)- thiazole-5-carbox- amide - The ability of the compounds of the present invention to inhibit Vaccinia virus was established by the following experimental procedure:
- (a) Preparation of Virus Stock:
- Virus stocks of Vaccinia virus (NYCBH) were prepared in Vero cells infected at low multiplicity (0.01 plaque forming units (PFU)/cell) and harvested when cytopathic effects were complete (4+CPE). The samples were frozen and thawed and then sonicated to release cell-associated virus. The cell debris was removed by low-speed centrifugation, and the resulting virus suspension was stored in 1 mL aliquots at −80° C. The PFU/mL of the virus suspension was quantified by standard plaque assay on Vero and BSC-40 cells.
- (b) Vaccinia CPE: Assay:
- To determine the amount of vaccinia virus stock required to produce complete CPE in 3 days, Vero cell monolayers were seeded on to 96-well plates and infected with 2-fold serial dilutions of the vaccinia virus stock. At 3 days post-infection, the cultures were fixed with 5% glutaraldehyde and stained with 0.1% crystal violet. Virus-induced CPE was quantified spectrophometrically at OD570. From this analysis, a 1:800 dilution of vaccinia virus stock was chosen for use in the HTS assay. This amount of vaccinia virus represents a multiplicity of infection of approximately 0.1 PFU/cell. To establish the signal-to-noise ratio (S/N) of the 96-well assay and evaluate the well-to-well and assay-to-assay variability, six independent experiments were performed. Vero cell monolayers were infected with 1:800 dilution of vaccinia virus stock. Each plate contained the following controls: quadruplicate virus-infected wells, quadruplicate uninfected cell wells and a dose response curve in duplicate for cidofovir (CDV) added at 300, 100, 30 and 10 DAM, or phosphonoacetic acid (PAA) added at 2100, 714, 210, and 71 μM as reference standards. At day 3 post-infection, the plates were processed as described above.
- The results of these experiments indicated that the 96-well assay format is robust and reproducible. The S/N ratio (ratio of signal of cell control wells (signal) to virus control wells (noise)) was 9.2±1.8. The well-to-well and assay-to-assay variability was less than 20%. Using this assay, the EC50 values for CDV and PAA were determined to be 84±15 μM and 985±85 μM, respectively. These values were within the range of published values for these compounds. Based on this analysis, the 1:800 dilution of vaccinia virus (boxed) was chosen for use in the assay.
- (c) Compound Testing:
- Representative compounds of the invention were tested in the vaccinia virus CPE assay. Compounds were dissolved in DMSO and diluted in medium such that the final concentration in each well was 5 μM compound and 0.5% DMSO. The compounds were added robotically to the culture medium using the Biomek® FX robot system. Following compound addition, the cultures were infected with vaccinia virus. After 3 days, plates were processed and CPE quantified as described.
- Representative compounds of the invention inhibited vaccinia virus-induced CPE by greater than 50% at the test concentration (5 μM). Selected compounds were further evaluated for potency (EC50) in the CPE assay and cytotoxicity (CC50) in an MTT assay. The MTT assay measures mitochondrial dehydrogenase activity in dividing cells. This method detects the in situ reduction of (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) using an electron coupling reagent (phenazine methosulfate) to produce an insoluble formazan. The absorbance of the formazan at 490 nm can be measured directly from 96-well assay plates following solubilization of the formazan in 50% ethanol. The quantity of formazan product is directly proportional to the number of living cells in culture.
- EC50 values are determined by comparing compound-treated and compound-untreated cells using a computer program. (The EC50 value measures compound concentration that inhibits viral replication by 50%). The EC50 values of representative compounds of the invention in the CPE assay are listed in Table 3, below. These compounds were active at non-toxic concentrations.
TABLE 3 Vaccinia EC50 Cowpox EC50 A = <0.5 μM, A = <0.5 μM, B = 0.5 to <1.0 μM, B = 0.5 to <1.0 μM, Example C = 1.0 to <5 μM C = 1.0 to <5 μM Number D = ≧5 μM D = ≧5 μM 1. A A 2. A C 3. A B 4. A C 5. A B 6. B D 7. A *** 8. A B 9. A D 10. D D 11. C D 12. A A 13. A B 14. A C 15. A A 16. A A 17. A C 18. A A 19. A A 20. A A 21. A A 22. A C 23. A *** 24. A B 25. B D 26. A *** 27. B *** 28. A A 29. A A 41. A C
*** Indicates that data was not collected.
- Several additional CPE inhibition assays, similar to above, were utilized to identify a spectrum of activity of compounds of the invention within the orthopox genus. For example, the corresponding EC50 values of representative compounds in wild type cowpox virus (obtained from USAMRIID, Fort Detrick, Frederick, Md.) are listed in Table 3, above.
- Table 4 lists EC50 values of select compounds of the invention measuring anti-orthopox virus activities in these CPE inhibition assays for cidofovir-resistant cowpox virus (Brighton Red strain, (available from USAMRIID Fort Detrick, Frederick, Md.), camelpox, and monkeypox virus (Zaire(V79-1-005-scab)).
TABLE 4 Cidofovir- Resistant Camelpox EC50 Cowpox EC50 Monkeypox EC50 A = <0.5 μM, A = <0.5 μM, A = <0.5 μM, B = 0.5 B = 0.5 to <1.0 μM, B = 0.5 to <1.0 μM, to <1.0 μM, Example C = 1.0 to <5 μM C = 1.0 to <5 μM C = 1.0 to <5 μM Number D = ≧50 μM D = ≧50 μM D = ≧50 μM 1 A A A 2 A A A 3 A A A 15 A A A 24 B A A - The specificity of representative compounds for orthopox virus inhibition is reflected in the fact that they do not inhibit the replication of unrelated viruses, including Pichinde virus, Rift Valley fever virus (strain MP12), respiratory syncytial virus and cytomegalovirus.
- Although the present invention has been described and exemplified in terms of certain preferred embodiments, other embodiments will be apparent to those skilled in the art. The invention is, therefore, not limited to the particular embodiments described and exemplified, but is capable of modification or variation without departing from the spirit of the invention, the full scope of which is delineated by the appended claims.
Claims (19)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/561,153 US7737168B2 (en) | 2003-06-20 | 2004-06-18 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US11/785,997 US7687641B2 (en) | 2003-06-20 | 2007-04-23 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
PCT/US2007/009750 WO2008079159A2 (en) | 2004-06-18 | 2007-04-23 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
CA002685198A CA2685198A1 (en) | 2004-06-18 | 2007-04-23 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US11/785,998 US8039504B2 (en) | 2003-06-20 | 2007-04-23 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
EP07867085A EP2192901A4 (en) | 2004-06-18 | 2007-04-23 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US12/643,641 US8124643B2 (en) | 2003-06-20 | 2009-12-21 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US12/752,462 US7956197B2 (en) | 2003-06-20 | 2010-04-01 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US13/194,437 US8530509B2 (en) | 2003-06-20 | 2011-07-29 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US13/966,392 US8802714B2 (en) | 2003-06-20 | 2013-08-14 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US14/323,587 US9045418B2 (en) | 2003-06-20 | 2014-07-03 | Compounds, compositions and methods for treatment and prevention of Orthopoxvirus infections and associated diseases |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48018203P | 2003-06-20 | 2003-06-20 | |
PCT/US2004/019552 WO2004112718A2 (en) | 2003-06-20 | 2004-06-18 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US10/561,153 US7737168B2 (en) | 2003-06-20 | 2004-06-18 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/019552 A-371-Of-International WO2004112718A2 (en) | 2003-06-20 | 2004-06-18 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/785,997 Continuation-In-Part US7687641B2 (en) | 2003-06-20 | 2007-04-23 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US11/785,998 Continuation-In-Part US8039504B2 (en) | 2003-06-20 | 2007-04-23 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US12/643,641 Division US8124643B2 (en) | 2003-06-20 | 2009-12-21 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US12/752,462 Division US7956197B2 (en) | 2003-06-20 | 2010-04-01 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
US20060235051A1 US20060235051A1 (en) | 2006-10-19 |
US20080103181A9 true US20080103181A9 (en) | 2008-05-01 |
US7737168B2 US7737168B2 (en) | 2010-06-15 |
Family
ID=39563279
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/561,153 Active 2031-09-04 US7737168B2 (en) | 2003-06-20 | 2004-06-18 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US12/643,641 Expired - Lifetime US8124643B2 (en) | 2003-06-20 | 2009-12-21 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US12/752,462 Expired - Lifetime US7956197B2 (en) | 2003-06-20 | 2010-04-01 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/643,641 Expired - Lifetime US8124643B2 (en) | 2003-06-20 | 2009-12-21 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US12/752,462 Expired - Lifetime US7956197B2 (en) | 2003-06-20 | 2010-04-01 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Country Status (4)
Country | Link |
---|---|
US (3) | US7737168B2 (en) |
EP (1) | EP2192901A4 (en) |
CA (1) | CA2685198A1 (en) |
WO (1) | WO2008079159A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070287735A1 (en) * | 2003-06-20 | 2007-12-13 | Siga Technologies, Inc. | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US20080004452A1 (en) * | 2003-06-20 | 2008-01-03 | Siga Technologies, Inc. | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US20080300265A1 (en) * | 2006-03-02 | 2008-12-04 | Siga Technologies Inc. | Antiviral drugs for treatment of arenavrus infection |
US20090203675A1 (en) * | 2004-12-06 | 2009-08-13 | Siga Technologies, Inc. | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses |
US20100167180A1 (en) * | 2007-04-06 | 2010-07-01 | Liangheng Xu | Photosensitive Film for Holographic Recording and Production Method Thereof |
US20100189685A1 (en) * | 2007-05-23 | 2010-07-29 | Byrd Chelsea M | Antiviral Drugs for Treatment or Prevention of Dengue Infection |
US20100227892A1 (en) * | 2003-06-20 | 2010-09-09 | Siga Technologies Inc. | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases |
US7872037B2 (en) | 2006-03-02 | 2011-01-18 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
US7994221B2 (en) | 2004-12-06 | 2011-08-09 | Siga Technologies, Inc. | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
US8410149B2 (en) | 2004-12-06 | 2013-04-02 | Siga Technologies Inc. | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
US8871746B2 (en) | 2006-03-02 | 2014-10-28 | Kineta Four, LLC | Antiviral drugs for treatment of arenavirus infection |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8530509B2 (en) | 2003-06-20 | 2013-09-10 | Siga Technologies, Inc. | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US8106058B2 (en) | 2006-02-01 | 2012-01-31 | Siga Technologies, Inc. | Anti-arenaviral compounds |
US8791110B2 (en) | 2006-02-01 | 2014-07-29 | Siga Technologies, Inc. | Anti-arenaviral compounds |
CA2698075C (en) | 2007-08-27 | 2016-04-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
WO2011119698A1 (en) | 2010-03-23 | 2011-09-29 | Siga Technologies, Inc | Polymorphic forms st-246 and methods of preparation |
US9546137B2 (en) | 2012-08-16 | 2017-01-17 | Siga Technologies Inc. | Methods of preparing Tecovirimat |
CA2930461C (en) | 2013-11-19 | 2022-08-16 | Siga Technologies, Inc. | Rehydration of micronized tecovirimat monohydrate |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029666A (en) * | 1967-08-09 | 1977-06-14 | Hoechst Aktiengesellschaft | Benzenesulfonyl-ureas and process for preparing them |
US4061763A (en) * | 1975-05-09 | 1977-12-06 | Merck & Co., Inc. | Tricyclicdicarboximides |
US4173646A (en) * | 1974-10-04 | 1979-11-06 | Merck & Co., Inc. | Tricyclicdicarboximides |
US6433016B1 (en) * | 2001-01-12 | 2002-08-13 | Vassil Stefanov Georgiev | Drugs for treating viral infections |
US20020193443A1 (en) * | 2001-01-12 | 2002-12-19 | Georgiev Vassil S. | Drugs for treating viral infections |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2906755A (en) * | 1956-11-16 | 1959-09-29 | Schenley Ind Inc | N-acyl derivatives of alpha-pyridine carboxylic acid hydrazide |
US5068356A (en) | 1990-02-20 | 1991-11-26 | Atochem North America, Inc. | Hindered phenolic n-(amido)imides |
US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US7737168B2 (en) | 2003-06-20 | 2010-06-15 | Siga Technologies, Inc. | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
DK1638938T3 (en) * | 2003-06-20 | 2017-07-31 | Siga Tech Inc | Compounds, Compositions and Methods for the Treatment and Prevention of Orthopox Virus Infections and Related Diseases |
US7687641B2 (en) | 2003-06-20 | 2010-03-30 | Siga Technologies, Inc. | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
CN101702904A (en) | 2007-04-23 | 2010-05-05 | 西佳技术公司 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
-
2004
- 2004-06-18 US US10/561,153 patent/US7737168B2/en active Active
-
2007
- 2007-04-23 CA CA002685198A patent/CA2685198A1/en not_active Abandoned
- 2007-04-23 WO PCT/US2007/009750 patent/WO2008079159A2/en active Application Filing
- 2007-04-23 EP EP07867085A patent/EP2192901A4/en not_active Withdrawn
-
2009
- 2009-12-21 US US12/643,641 patent/US8124643B2/en not_active Expired - Lifetime
-
2010
- 2010-04-01 US US12/752,462 patent/US7956197B2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029666A (en) * | 1967-08-09 | 1977-06-14 | Hoechst Aktiengesellschaft | Benzenesulfonyl-ureas and process for preparing them |
US4173646A (en) * | 1974-10-04 | 1979-11-06 | Merck & Co., Inc. | Tricyclicdicarboximides |
US4061763A (en) * | 1975-05-09 | 1977-12-06 | Merck & Co., Inc. | Tricyclicdicarboximides |
US6433016B1 (en) * | 2001-01-12 | 2002-08-13 | Vassil Stefanov Georgiev | Drugs for treating viral infections |
US20020193443A1 (en) * | 2001-01-12 | 2002-12-19 | Georgiev Vassil S. | Drugs for treating viral infections |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110009456A1 (en) * | 2003-06-20 | 2011-01-13 | Siga Technologies Inc. | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases |
US20080004452A1 (en) * | 2003-06-20 | 2008-01-03 | Siga Technologies, Inc. | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US8039504B2 (en) | 2003-06-20 | 2011-10-18 | Siga Technologies, Inc. | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US20070287735A1 (en) * | 2003-06-20 | 2007-12-13 | Siga Technologies, Inc. | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US7687641B2 (en) | 2003-06-20 | 2010-03-30 | Siga Technologies, Inc. | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US7956197B2 (en) | 2003-06-20 | 2011-06-07 | Siga Technologies, Inc. | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US8124643B2 (en) | 2003-06-20 | 2012-02-28 | Siga Technologies, Inc. | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
US20100227892A1 (en) * | 2003-06-20 | 2010-09-09 | Siga Technologies Inc. | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases |
US8664274B2 (en) | 2004-12-06 | 2014-03-04 | Siga Technologies, Inc. | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses |
US8642596B2 (en) | 2004-12-06 | 2014-02-04 | Siga Technologies, Inc. | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses |
US9067873B2 (en) | 2004-12-06 | 2015-06-30 | Kineta Four, LLC | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
US20090203675A1 (en) * | 2004-12-06 | 2009-08-13 | Siga Technologies, Inc. | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses |
US8410149B2 (en) | 2004-12-06 | 2013-04-02 | Siga Technologies Inc. | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
US7994221B2 (en) | 2004-12-06 | 2011-08-09 | Siga Technologies, Inc. | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
US9115065B2 (en) | 2004-12-06 | 2015-08-25 | Kineta, Inc. | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses |
US8629170B2 (en) | 2006-03-02 | 2014-01-14 | Siga Technologies, Inc. | Anti-viral drugs for treatment of arenavirus infection |
US20110172281A1 (en) * | 2006-03-02 | 2011-07-14 | Siga Technologies Inc. | Anti-Viral Drugs for Treatment of Arenavirus Infection |
US7977365B2 (en) | 2006-03-02 | 2011-07-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
US7872037B2 (en) | 2006-03-02 | 2011-01-18 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
US8871746B2 (en) | 2006-03-02 | 2014-10-28 | Kineta Four, LLC | Antiviral drugs for treatment of arenavirus infection |
US20080300265A1 (en) * | 2006-03-02 | 2008-12-04 | Siga Technologies Inc. | Antiviral drugs for treatment of arenavrus infection |
US20100167180A1 (en) * | 2007-04-06 | 2010-07-01 | Liangheng Xu | Photosensitive Film for Holographic Recording and Production Method Thereof |
US8518960B2 (en) | 2007-05-23 | 2013-08-27 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
US20100189685A1 (en) * | 2007-05-23 | 2010-07-29 | Byrd Chelsea M | Antiviral Drugs for Treatment or Prevention of Dengue Infection |
US9353051B2 (en) | 2007-05-23 | 2016-05-31 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
Also Published As
Publication number | Publication date |
---|---|
WO2008079159A3 (en) | 2008-10-09 |
EP2192901A2 (en) | 2010-06-09 |
US20110009456A1 (en) | 2011-01-13 |
US7737168B2 (en) | 2010-06-15 |
US7956197B2 (en) | 2011-06-07 |
US8124643B2 (en) | 2012-02-28 |
US20060235051A1 (en) | 2006-10-19 |
EP2192901A4 (en) | 2010-10-13 |
US20100227892A1 (en) | 2010-09-09 |
CA2685198A1 (en) | 2008-07-03 |
WO2008079159A2 (en) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7956197B2 (en) | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | |
US8039504B2 (en) | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | |
JP5657489B2 (en) | Compounds, compositions and methods for treating and preventing orthopoxvirus infection and related diseases | |
US7687641B2 (en) | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | |
US9045418B2 (en) | Compounds, compositions and methods for treatment and prevention of Orthopoxvirus infections and associated diseases | |
AU2012268859B2 (en) | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | |
AU2016208315A1 (en) | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SIGA TECHNOLOGIES, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VIROPHARMA INCORPORATED;REEL/FRAME:015479/0526 Effective date: 20041201 Owner name: SIGA TECHNOLOGIES, INC.,NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VIROPHARMA INCORPORATED;REEL/FRAME:015479/0526 Effective date: 20041201 |
|
AS | Assignment |
Owner name: PHARMATHENE, INC., MARYLAND Free format text: SECURITY AGREEMENT;ASSIGNOR:SIGA TECHNOLOGIES, INC.;REEL/FRAME:017387/0237 Effective date: 20060320 Owner name: PHARMATHENE, INC.,MARYLAND Free format text: SECURITY AGREEMENT;ASSIGNOR:SIGA TECHNOLOGIES, INC.;REEL/FRAME:017387/0237 Effective date: 20060320 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: SIGA TECHNOLOGIES, INC., NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:PHARMATHENE, INC.;REEL/FRAME:025721/0416 Effective date: 20110124 |
|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:SIGA TECHNOLOGIES, INC.;REEL/FRAME:027363/0968 Effective date: 20111107 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
REFU | Refund |
Free format text: REFUND - PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: R1551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: SIGA TECHNOLOGIES, INC., NEW YORK Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYANCE TYPE PREVIOUSLY RECORDED AT REEL: 025721 FRAME: 0416. ASSIGNOR(S) HEREBY CONFIRMS THE TERMINATION AND RELEASE OF SECURITY INTEREST;ASSIGNOR:PHARMATHENE, INC.;REEL/FRAME:039753/0670 Effective date: 20110124 |
|
AS | Assignment |
Owner name: CORTLAND CAPITAL MARKET SERVICES, LLC, ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:SIGA TECHNOLOGIES, INC.;REEL/FRAME:040349/0219 Effective date: 20161116 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552) Year of fee payment: 8 |
|
AS | Assignment |
Owner name: VIROPHARMA INCORPORATED, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JORDAN, ROBERT;BAILEY, THOMAS R.;RIPPIN, SUSAN R.;SIGNING DATES FROM 20041124 TO 20041206;REEL/FRAME:046709/0937 |
|
PTEF | Application for a patent term extension |
Free format text: PRODUCT NAME: TPOXX (TECOVIRIMAT); REQUESTED FOR 1585 DAYS Filing date: 20180904 Expiry date: 20270503 |
|
AS | Assignment |
Owner name: SIGA TECHNOLOGIES, INC., NEW YORK Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 40349/0219;ASSIGNOR:CORTLAND CAPITAL MARKET SERVICES LLC;REEL/FRAME:052163/0014 Effective date: 20200312 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |